PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 1Title Page
A SINGLE -DOSE, OPEN -LABEL, RANDOM IZED, [ADDRESS_660018], CROSS -OVER PI [INVESTIGATOR_510425], FOR
SPI[INVESTIGATOR_383188]/HYDROCHLOROTHIAZIDE FILM COATED TABLETS IN
HEALTHY ADULT PARTI CIPANTS UNDER FASTED CONDITIONS
Study Intervention Number: PF-06832640
Study Intervention Name: [CONTACT_84899][INVESTIGATOR_8407]/Hy drochlorothiazide
US IND Number: NDA [ADDRESS_660019] Number: Notapplicable
ClinicalTrials.gov ID: Not applicable
Pediatric Investigational Plan Number: Not applicable
Protocol Number: B9531002
Phase: 1
Sponsor Legal Address: [COMPANY_007] I nc.
[ADDRESS_660020]
[LOCATION_001], NY [ZIP_CODE]
Brief Title: Pi[INVESTIGATOR_510426] y of Spi[INVESTIGATOR_8407]/Hy drochlorothiazide Film 
Coated Tablets to Qualify  Manufacturing Site Transfer From Viatris to Neolpharma.
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_185586] s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_87117] ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 2Document History
Document Version Date
Original protocol 28September 2023

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 3TABLE OF CONTENTS
LIST OF TABLES ................................................................ ................................ ..................... 7
1. PROTOCOL  SUMMARY .....................................................................................................8
1.1. Sy nopsis ....................................................................................................................8
1.2. Schema ....................................................................................................................12
1.3. Schedule of Activities .............................................................................................13
2. INTRODUCTION ...............................................................................................................18
2.1. Study  Rationale .......................................................................................................18
2.2. Background .............................................................................................................18
2.2.1. Clini cal Overview .......................................................................................19
2.3. Benefit/Risk Assessment................................
.........................................................20
2.3.1. Risk Assessment ................................
.........................................................21
2.3.2. Benefit Assessment .....................................................................................22
2.3.3. Overall Benefit/Risk Conclusion ................................................................22
3. OBJECTIVES AND EN DPOINTS ................................
.....................................................22
4. STUDY DESIGN .................................................................................................................22
4.1. Overall Design .........................................................................................................22
4.2. Scientific Rationale for Study  Design .....................................................................23
4.2.1. Choice of Contraception/Barrier Requirements .........................................24
4.3. Justification for Dose ..............................................................................................24
4.4. End of Study  Definition ..........................................................................................24
5. STUDY POPUL ATION ................................
......................................................................24
5.1. I nclusion Criteria .....................................................................................................25
5.2. Exclusion Criteria ....................................................................................................25
5.3. L ifesty le Considerations ..........................................................................................27
5.3.1. Contraception ..............................................................................................27
5.3.2. Meals and Dietary  Restrictions ................................ ................................ ...27
5.3.3. Caffeine, Alcohol, and Tobacco ................................ ................................ .28
5.3.4. Activity .......................................................................................................28
5.4. Screen Failures ........................................................................................................29
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY ................................ .29
6.1. Study  Intervention(s) Administered ........................................................................29

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 46.1.1. Administration ............................................................................................30
6.2. Preparation, Handling, Storage, and Accountability ...............................................30
6.2.1. Preparation and Dispensing ........................................................................31
6.3. Assignment to Study I ntervention ...........................................................................32
6.4. Blinding................................
...................................................................................32
6.5. Study  Intervention Compliance ...............................................................................32
6.6. Dose Modification ...................................................................................................32
6.7. Continued Access to Study  Intervention After the End of the Study ......................32
6.8. Treatment of Overdose................................
............................................................32
6.9. Prior and Concomitant Therap y ................................
..............................................33
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ................................
...........................................33
7.1. Discontinuation of Study  Intervention ....................................................................33
7.1.1. Potential Cases of Acute Kidney  Injury .....................................................34
7.1.2. ECG Changes ..............................................................................................35
7.1.3. Pregnancy ...................................................................................................35
7.1.4. COVID -19
..................................................................................................36
7.2. Partici pant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_660021] to Follow -Up...................................................................................................37
8. STUDY ASSESSMENTS A
ND PROCEDURES...............................................................37
8.1. Administrative Procedures ......................................................................................37
8.2. Efficacy  Assessments ..............................................................................................38
8.3. Safet y Assessments .................................................................................................38
8.3.1. Phy sical Examinations ................................................................................38
8.3.2. Vital Signs ..................................................................................................39
[IP_ADDRESS]. Blood Pressure and Pulse Rate ..................................................39
8.3.3. Electrocardiograms................................
.....................................................39
8.3.4. Clinical Safety  Laboratory  Assessments ....................................................40
[IP_ADDRESS]. Alternative Facilities for Clinical Safety  Laboratory  
Assessment ........................................................................................40
8.3.5. Pregnancy  Testing ................................ ................................ ...................... 40
8.4. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................41

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 58.4.1. Time Period and Frequency  for Collecting AE and SAE Information .......41
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................42
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................42
8.4.2. Method of Detecting AEs and SAEs ..........................................................42
8.4.3. Follow -Up of AEs and SAEs ................................
......................................42
8.4.4. Regulatory Reporting Requirements for SAEs ...........................................43
8.4.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................43
[IP_ADDRESS]. Exposure During Pregnancy ......................................................43
[IP_ADDRESS]. Exposure Du ring Breastfeeding ................................................45
[IP_ADDRESS]. Occupational Exposure .............................................................45
8.4.6. Cardiovascular and Death Events ...............................................................
46
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualify
ing as AEs or SAEs ..............................................................................[ADDRESS_660022].............................................................46
[IP_ADDRESS]. Lack of Eff icacy ................................
........................................46
8.4.9. Medical Device Deficiencies ......................................................................46
8.4.10. Medication Errors .....................................................................................46
8.5. Pharmacokinetics ................................ ................................ ................................ ....47
8.6. Genetics ...................................................................................................................48
8.6.1. Specified Genetics ......................................................................................48
8.6.2. Retained Research Samples for Genetics ...................................................48
8.7. Biomarkers ................................
..............................................................................48
8.8. I mmunogenicit y Assessments .................................................................................48
8.9. Health Economics ...................................................................................................48
9. STATI STICAL CONSI DERATIONS ................................
................................................48
9.1. Statistical Hy pothesis ..............................................................................................49
9.2. Analy sis Sets ...........................................................................................................49
9.3. Statistical Analy ses.................................................................................................49
9.3.1. General Considerations ................................ ................................ ............... 50
9.3.2. Primary  Endpoint(s) Anal ysis................................ ................................ .....50
9.3.3. Secondary  Endpoint(s) Anal ysis................................ ................................ .51
9.3.4. Safet y Anal yses................................ ................................ .......................... 51

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 69.3.5. Other Anal yses............................................................................................51
9.4. I nterim Anal yses.....................................................................................................51
9.5. Sample Size Determination .....................................................................................52
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ................................
..........................................................................53
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Consi derations ...............53
10.1.1. Regulatory and Ethical Considerations ....................................................53
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................53
10.1.2. Financial Disclosure .................................................................................54
10.1.3. I nformed Consent Process ........................................................................54
10.1.4. Data Protection .........................................................................................55
10.1.5. Committees Structure ...............................................................................55
[IP_ADDRESS]. Data Monitoring Committee ...................................................55
10.1.6. Dissemination of Clinical Study  Data ................................ ...................... 56
10.1.7. Data Qualit y Assurance ............................................................................57
10.1.8. Source Documents ....................................................................................58
10.1.9. Use of Medical Records ................................ ................................ ............ 58
10.1.10. Study  and Site Start and Closure ............................................................59
10.1.11. Publication Policy ...................................................................................60
10.1.12. Sponsor’s Medically  Qualified Individual ................................ .............. 60
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................62
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................63
10.3.1. Definition of AE .......................................................................................63
10.3.2. Definition of an SAE ................................................................................64
10.3.3. Recording/Reporting and Follow- Up of AEs and/or SAEs During 
the Active Collection Period ................................
............................................65
10.3.4. Reporting of SAEs................................
....................................................69
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................70
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................70
10.4.2. Female Participant Reproductive Inclusion Criteria ................................ .70
10.4.3. Woman of Childbearing Potential ................................ ............................ 71

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 710.4.4. Contraception Me thods .............................................................................72
10.5. Appendix 5: Genetics ............................................................................................73
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments .......75
10.7. Appendix 7: Kidney  Safety : Monitoring Guidelines ............................................77
10.7.1. Laboratory  Asses sment of Change in Kidney Function and 
Detection of Kidney  Injury ................................
..............................................77
10.7.2. Age -Specific Kidney  Function Calculation Recommendations ...............77
[IP_ADDRESS]. Adults (18 Years and Above) —
2021 CKD -EPI 
[INVESTIGATOR_185560]
...........................................................................................77
10.7.3. Kidney  Function Calculation Tools ..........................................................78
10.7.4. Adverse Event Grading for Kidney  Safet y Laboratory  
Abnormalities ...................................................................................................78
10.8. Appendix 8: ECG Findings of Potential Clinical Concern ...................................79
10.9. Appendix 9: Prohibited Concomitant Medications That May Result in DDI .......81
10.10. Appendix 10: Abbreviations ................................
...............................................[ADDRESS_660023] OF TABLES
Table 1. Study  Schedule of Assessment ................................ ................................ .13
Table 2. Pharmacokinetic Sampling Times (Period 1 and Period 2)......................17
Table 3. Treatment Sequence ..................................................................................23
Table 4. PK Parameters ..........................................................................................50
Table 5. Protocol -Required Laboratory  Assessments .............................................62

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 81.PROTOCOL SUMMARY
1.1.Synopsis
Protocol Title: A single -dose, open -label, randomized, [ADDRESS_660024], cross -over pi[INVESTIGATOR_510427] y to qualify manufacturing site transfer from Viatris to Neolpharma, for 
Spi[INVESTIGATOR_8407]/Hy
drochlorothiazide film coated tablets in healthy adult participants under 
fasted conditions.
BriefTitle: Pi[INVESTIGATOR_510428] y of Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated 
tablets to qualify  manufacturing site transfer from Viatris to Neolpharma.
Regulatory Agency Identification Number(s):
US IND Number: NDA [ADDRESS_660025] Number: Not applicable
ClinicalTrials.gov ID: Not applicable
Pediatric Investigational Plan Number: Not applicable
Protocol Number: B9531002
Phase: 1
Rationale :
The purpose of this stud y is to assess the bioequivalence (BE) between 
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets manufactured at Viatris 
Pharmaceuticals LL C, Puerto Rico ( hereafter referred to as Viatris) and 
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets manufactured at Neolpharma, Inc., 
Puerto Rico ( hereafter referred to as Neolpharma).
Objectives and Endpoints:
Objectives Endpoints
Prim ary: Prim ary:
To demonstrate bioequivalence betw een 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 25 mg/25mg 
film coated tablets manufactured at the proposed 
site (Neolpharma) vs 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 25 mg/25mg 
film coated tablets manufactured at current site 
(Viatris) under fasting conditions in healthy adult 
participants.Maximum observed concentration (Cmax), area 
under the plasma concentration -time profile 
from time 0 extrapolated to infinite time 
(AUC inf)(or AUC lastif AUC infcannot be 
reliably estimated) of Spi[INVESTIGATOR_8407] a nd 
Hydrochlorothiazide.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 9Objectives Endpoints
Secondary: Secondary:
To further characterize pharmacokinetic(s) ( PK)of 
Spi[INVESTIGATOR_510429].
To evaluate the safety and tolerability of 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide film coated 
tablets.Terminal elimination half -life(t½)(if data 
permit) and time for C max(Tmax)of 
Spi[INVESTIGATOR_510429].
Adverse events (AEs), clinical laboratory tests, 
vital signs, and ECGs.
Overall Design :
This will be an open -label, randomized, single- dose, 2 -treatment, 2 -period, 2- sequence, 
crossover stud y in adult healthy male and/or female participant s.
Number of Participants:
Approximately  40 participants will be enrolled in the study .
Note: “ Enrolled ”means a participant ’s, or their legall y authorized representative’s, 
agreement to participate in a clinical study
 following completion of the informed consent 
process and randomization/assignment to study  intervention .
Study Population :
Key inclusion and exclusion criteria are listed below:
Inclusion Criteria
Participants must meet the following key  inclusion criteria to be eligible for enrollment into 
the study :
1.Male and f emale participants must be 18 to 75 y ears of age, inclusive, at the time of 
signing the informed consent document (ICD).
2.Body mass index (BMI )of 16 -32 kg/m2; and a total body  weight >50 kg (110 lb).
Exclusion Criteria
Participants with any  of the following characteristics/conditions will be excluded:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurological, or 
allergic disease (including drug aller gies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing).

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 10Any condition possibly  affecting drug absorption (eg, gastrectomy , 
cholecy stectom y).
History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, 
HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
2.Baseline 12-lead electrocardiogram ( ECG) thatdemonstrates clinically relevant 
abnormalities that may affect participant safety or interpretation of study results (eg,
baseline corrected QT (QTc) interval >450 msec.
Study Arms and Duration:
Approximately  40 
participants will be enrolled in the study  (20 in each treatment sequence). 
Participant s will be assigned to 1
of the following 2 sequences according to a 
computer -generated randomization schedule. There wil l be a minimum 4-day washout period 
between successive doses (ie, administration of subsequent doses of stud y medication will 
not occur until at least 4days after the previous dose of study  medication).
Study Intervention(s)
Intervention Name [CONTACT_84899][INVESTIGATOR_8407]/Hydrochlorothiazide Spi[INVESTIGATOR_8407]/Hydrochlorothiazide
Use Reference Product Test Product
IMP or NIMP/AxMP NIMP IMP
Dose Form ulation Film coated tablet s Film coated tablet s
Unit Dose Strength(s) 25 mg/25 mg 25 mg/25 mg
Route of Adm inistration Oral Oral
Abbreviations: AxMP =auxiliary medicinal product; IMP =investigational medicinal product;
NIMP =noninvestigational medicinal product .
Study Arm(s)
Arm  Title Treatment A (Reference) Treatment B (Test)
Arm  Description Participants will receive 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 
25mg/25 mg film coated tablet 
manufactured at Viatris on Day 1 of 
each treatment period.Participants will receive 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 
25mg/25 mg film coated tablet 
manufactured at Neolpharma on Day 1 
of each treatment period.
Statistical Methods :
A sample size of 38 evaluable participants will provide ≥ 99.9% and 91.0% power that the 
90% confidence interval (CI) for the ratio of Test to Reference treatment for C maxand AUC inf

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 11(or AUC lastif AUC infcannot be reliabl y estimated) of spi[INVESTIGATOR_8407] , respectively , will lie 
within the acceptance region of (80%, 125%). Additionally , it will provide ≥99.6% and 
≥99.0% power that the 90% CIs for the ratios of Test to Reference treatment f or AUC infand 
Cmaxof Hy drochlorothiazide (HCTZ) will lie within the acceptance region of (80%, 125%). 
Consequently , this study  will have approximately  90% overall power to demonstrate BE of 
the Test treatment to the Reference treatment (ie, equivalence fo r both 
AUC infand C max) of 
both spi[INVESTIGATOR_510430], where overall power for the study  is based on the product of 
the individual powers of the parameters of interest.
Bioequivalence of the Test treatment to Reference treatment will be concluded if the 
90% CIs for the ratios of adjusted geometric means for both spi[INVESTIGATOR_510431] C maxfall entirely  within the acceptance region of (80%, 
125%).
Ethical Considerations:
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets arenot expected to provide any  
clinical benefit to healthy participants. This study is designed primaril y to generate 
pharmacokinetic and tolerability  data of spi[INVESTIGATOR_74963] h ydrochlorothiazide to support 
regulatory  registration of Spi[INVESTIGATOR_8407]/Hy droch lorothiazide film coated tablets at 
25mg/25 mg strength manufactured at Neolpharma .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 121.2.Schema
Treatment Sequence
Sequence Number of Participants Period [ADDRESS_660026] 4days Treatment B
2 20 Treatment B Treatment A
Treatment A: Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 25 mg/25 mg film coated tablets manufactured at the 
current site (Viatris) under fasting conditions.
Treatment B: Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 25 mg/25 mg film coated tablets manufactured at the 
proposed site (Neolpharma) under fasting conditions.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 131.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the 
STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol.
The investigator may  sche dule visits (unplanned visits) in addit ion to those listed in the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Table 1.Study Schedule of Assessment
Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 1 0.Screen ing Period 1 Period 2 F/U Early 
DiscontinuationNotes
Days Relative to Day 1 Day -28 to Day -2Day -1Day 1 Day 2 Day 3 Day 1Day 2 Day 328-35
Days All screening should be done 
≤28days before the first dose.
 Day relative to start of study 
intervention (Day 1).
 A washout period of at least 4 days 
(96hours) will be required between 
the 2 doses.
 Follow -up may occur via telephone 
contact [INVESTIGATOR_1238] m ust occur 28 to 
35days after administration of the 
final dose of study intervention.
Hours After Dose 0 24 48 0 24 48
Informed consent X  Informed consent should be 
obtained prior to undergoing any 
study -specific procedure s.
 See Section 10.1.3 for additional 
information.
CRU confinement X      X  Participants will enter CRU on 
Day -1and stay in CRU until 
completion of Period 2 PK blood 
sampling .
Inclusion/exclusion 
criteriaX X

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 14Table 1.Study Schedule of Assessment
Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 1 0.Screen ing Period 1 Period 2 F/U Early 
DiscontinuationNotes
Days Relative to Day 1 Day -28 to Day -2Day -1Day 1 Day 2 Day 3 Day 1Day 2 Day 328-35
Days All screening should be done 
≤28days before the first dose.
 Day relative to start of study 
intervention (Day 1).
 A washout period of at least 4 days 
(96hours) will be required between 
the 2 doses.
 Follow -up may occur via telephone 
contact [INVESTIGATOR_1238] m ust occur 28 to 
35days after administration of the 
final dose of study intervention.
Hours After Dose 0 24 48 0 24 48
Medical/medication 
historyX X
Physical examinations X X X
Safety laboratory X X X  Safety laboratory includes 
hematology, chemistry, and 
urinalysis, which are list ed in 
Appendix 2.
 Laboratory safety tests will be 
obtained after fasting for at least 
8hours.
Demography, age, weight 
and heightX
Illegal
drug/tobacco/alcohol useX X  For confirmation of no 
drug/tobacco/alcohol use .
Urine alcohol test or
alcohol breath testX X
Urine Pregnancy test 
(WOCBP only)X X X  See Section 8.3.5 for additional 
information.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 15Table 1.Study Schedule of Assessment
Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 1 0.Screen ing Period 1 Period 2 F/U Early 
DiscontinuationNotes
Days Relative to Day 1 Day -28 to Day -2Day -1Day 1 Day 2 Day 3 Day 1Day 2 Day 328-35
Days All screening should be done 
≤28days before the first dose.
 Day relative to start of study 
intervention (Day 1).
 A washout period of at least 4 days 
(96hours) will be required between 
the 2 doses.
 Follow -up may occur via telephone 
contact [INVESTIGATOR_1238] m ust occur 28 to 
35days after administration of the 
final dose of study intervention.
Hours After Dose 0 24 48 0 24 48
Contraception check X X X X  For confirmation of appropriate use 
only.
 See Section 5.3.1 for additional 
information.
FSH (Post menopausal 
women only)X
Urine drug testing X
Single supi[INVESTIGATOR_050] 12 -Lead 
ECGX X  See Section 8.3.3 for additional 
information.
Blood pressure ,pulse rate X X  See Section [IP_ADDRESS] for additional 
information.
HIV, HBsAg, HBcAb,
HCVAb X
Study intervention
administrationX X  A washout period of at least 4 days 
(96hours) will be required between 
the 2 doses.
 The 1stdose willbe administered on 
Study Day 1 (Period 1 Day 1) and 
the 2nddose willbe administered on 
Study Day 5 (Period 2 Day 1).
Pharmacokinetic blood 
samplingX X X X X X X  Refer to PK sampling times table 
(Table 2).

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 16Table 1.Study Schedule of Assessment
Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 1 0.Screen ing Period 1 Period 2 F/U Early 
DiscontinuationNotes
Days Relative to Day 1 Day -28 to Day -2Day -1Day 1 Day 2 Day 3 Day 1Day 2 Day 328-35
Days All screening should be done 
≤28days before the first dose.
 Day relative to start of study 
intervention (Day 1).
 A washout period of at least 4 days 
(96hours) will be required between 
the 2 doses.
 Follow -up may occur via telephone 
contact [INVESTIGATOR_1238] m ust occur 28 to 
35days after administration of the 
final dose of study intervention.
Hours After Dose 0 24 48 0 24 48
Retained Research 
Sample for Genetics 
(Prep D1)X  Prep D1 Retained Research 
Samples for Genetics: If not 
collected on the designated 
collection day, collect at the next 
available time point when 
biospecimens are being collected in 
conjunction with a participant visit.
CRU discharge X
Concomitant medications X X X X X X X X
Serious and nonserious 
AEmonitoringX X X X X X X X X X  See Section 8.4.3for follow -up AE 
and SAE assessments.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 17Table 2. Pharmacokinetic Sampling Times (Period 1 and Period 2)
Visit Identifier Period 1 and Period 2 Notes
Study Day 1 2 3
Hours Before/After Dose 00.25 0.5 11.5 22.5 3 4 6 8 10 12 24 36 48 Hour 0 = predose sample 
collection
Study inte rvention 
administrationX
PK blood sampling X X X X X X X X X X X X X X X X Predose PK sample to be 
collected prior to dosing

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 182.INTRODUCTION
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tabl ets are a combination of [ADDRESS_660027] different but 
complementary  mechanisms and sites of action, thereby  [CONTACT_510463].
2.1.Study Rationale
[COMPANY_007] I nc. is a marketing authorization holder for Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film 
coated tablets. It is currentl y marketed in the [LOCATION_002] as 25 mg/25 mg 
(Spi[INVESTIGATOR_8407]/Hy drochlorothiazide) film coated tablets.
Currently  Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets are manufactured at Viatris 
Pharmaceuticals LL C, Puerto Rico (hereafter re ferred to as Viatris) . PGS intends to transfer 
drug product manufacturing operations for Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated 
tablets from the currentl y registered Viatris manufacturing site to the proposed Neolpharma, 
Inc., Puerto Rico (hereafte r referred to as Neolpharma) manufacturing site. The f
2 could not 
be calculated due to high %RSD values (high variability ). Bootstrap f2 analy sis was 
performed, and the similarity  factor calculated was outside of acceptable range. The 
comparative dissolution profile data between existing site and proposed new site when tested 
in release media failed as the similarity  factor (f2) calculated did not pass the criterion (f2 
value being <50) for both s pi[INVESTIGATOR_74963] h ydrochlorothiazide in release media tested . 
Therefore, this BE stud y is being conducted to qualify  the manufacturing site transfer, and 
the associated process changes, b y demonstrating BE between 
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets manufactured at the proposed site 
(Neolpharma ) versus existing site ( Viatris ).
The primary  objective of this study  is to assess the BE between 
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide 25mg/25mg film coated tablets manufactured at 
Viatris and Spi[INVESTIGATOR_8407]/Hy drochlorothiazide 25mg/25mg film coated tablet s 
manufactured at Neolpharma .
2.2.Background
The current Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets manufacturing needs to 
be transferred from Viatris to Neolpharma .The f2could not be calculated due to high %RSD 
values (high variabilit y). Bootstrap f2analysis was performed, and the similarity  factor 
calculated was outside of acceptable range. The comparative dissolution profile data between 
existing site and proposed new site when tested in release media failed as the similarity  factor 
(f2) calculated did not pass the criterion (f2 value being <50) for both spi[INVESTIGATOR_510432]. Hence, this BE study  is being conducted to 
qualify  the manufacturing site transfer from Viatris to Neolpharma.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 192.2.1. Clinical Overview
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated ta bletsarea combination of [ADDRESS_660028] different but complementary  
mechanisms and sites of action, thereb y providing additive diuretic and antihypertensive 
effects. T he spi[INVESTIGATOR_510433]/Hy drochlorothiazide film coated 
tablet shelps to minimize the potassium loss characteristically  induced by  [CONTACT_510464].
The diuretic effect of spi[INVESTIGATOR_510434] a specific 
pharmacologic antagonist of aldosterone, primarily  by [CONTACT_510465] -dependent sodium -potassium exchange site in the distal convoluted renal tubule. 
HCTZ promotes the excretion of sodium and water primarily  by [CONTACT_37951] g their reabsorption 
in the cortical diluting segment of the distal renal tubule.
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide is effective in significantl y lowering the systolic and 
diastolic blood pressure in many  patients with essential hy pertension, even when al dosterone 
secretion is within normal limits.
Both spi[INVESTIGATOR_510435], plasma volume, body  weight, 
and blood pressure. The diuretic and antih ypertensive effects of the individual components 
are potentiated when spi[INVESTIGATOR_510436] y.
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide is contraindicated in patients with acute renal 
insufficiency , significant renal compromise, anuria, Addison’s disease; significant 
hypercalcemia; hy perkalemia, or hy persensitivity  to spi[INVESTIGATOR_8407], thiazide diuretics, or to 
other sulfonamide -derived drugs.
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets formulations are available in 
strengths of 25 mg/25 mg (Spi[INVESTIGATOR_8407]/Hy drochlorothiazide).
Following oral administration, sp ironolactone rapi[INVESTIGATOR_510437] [ADDRESS_660029] dosing. Following oral administration of a single 
100 mg dose of spi[INVESTIGATOR_8407], the mean AUC infof spi[INVESTIGATOR_510438]  
154ng•hr/mL, mean C maxwas 4 8.3 ng/mL and elimination half -life of 2 to 3 hours (Xu et al, 
2008). Food increased the bioavailability  of unmetabolized spi[INVESTIGATOR_510439] 100%. 
The clinical importance of this finding is not known ( USPI , 09 January  2023 )
.
Spi[INVESTIGATOR_510440]. 
Following deacet ylation and S -methy lation, spi[INVESTIGATOR_510441] 
7-α-thiomethy lspi[INVESTIGATOR_8407], a sulfur- containing active metabo lite that is considered the 
major metabolite of spi[INVESTIGATOR_510442]. Sulfur -containing products are tho
ught to be 
primarily  responsible, together with spi[INVESTIGATOR_8407], for the therapeutic effects of the drug. 
Approximately  25% to 30% of spi[INVESTIGATOR_510443] (non- sulfur -containing active metabolite) (CDS, 14 April 2022 ). 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 20Spi[INVESTIGATOR_510444] 90% bound to plasma proteins. The 
metabolites are excreted primarily  in the urine and secondaril y in bile.
In a PKstudy  in 5healthy  male volunteers receiving spi[INVESTIGATOR_8407] 500 mg, 47% to 57% of 
the dose was excreted in the urine within 6 day s and the remaining amoun t could be detected 
in the feces (total recovery 90%). In another stud y in 5healthy  men, after a single 200 mg 
(with radioactive tracer) dose of spi[INVESTIGATOR_510445], over 5 days, 31.6% ± 5.87% 
of the radioactivity  was excreted in the urine mainl y as metabolites and 22.7% ± 14.1% in the 
feces (CDS, 14 April 2022 )
.
HCTZ is rapi[INVESTIGATOR_510446]. HCTZ peak plasma concentrations 
reached within 1 to 2 hours. Concurrent administration of HCTZ with food has resulted in 
significant decreases in plasma drug levels as compared to the administration of HCTZ in a 
fasted state (USPI , 09 January  2023). Following oral administration of a single 50 mg dose of 
hydrochlorthiazide, the mean AUC infof hy drochlorthiazide was approximately  
1730 ng•hr/mL, mean C maxwas 281 ng/mL and elimination half -life of approximately  
10hours (Fierro Humberto, 2016 ).
HCTZ is approximately  40% protein bound and accumulates in ery throcy tes by  [CONTACT_510466]. The ratio between red blood corpuscles and plasma is 3.5:1. The volume of 
distribution of HCTZ is a pproximately  3 L/kg to 4 L /kg(CDS, 14 April 2022
).
HCTZ undergoes onl y slight metabolic alteration and is excreted unchanged in urine. 
Following oral administration of 4 different doses (12.5 mg, 25 mg, 50 mg and 75 mg) of 
HCTZ to 8 healthy  volunteers, renal clearance ranged between 319 mL /min and 345 mL /min. 
HCTZ is excreted unchanged in the urine and appears in the urine within 1 hour of dosing. 
Approximately  50% to 70% was recovered in the urine within 24 hours after the oral 
administration of 25 mg to 65 mg of HCTZ .
Spi[INVESTIGATOR_510447], thus 
unnecessary  use of this drug should be avoided.
2.3.Benefit/Risk Assessment
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets are not expected to provide any  
clinical benefit to healthy participants. Th is study  is designed primaril y to generate safety, 
tolerability , and PKdata for further clinical development.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablet smay be found in the 
package insert , which is the SRSD for this study . Refer to the Study  Intervention(s) table in 
Section 6.1for a complete description of SRSDs.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 212.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) : Spi[INVESTIGATOR_8407]/Hydrochlorothiazide Film Coated Tablets
Tumorigenic The potential risk is based on pre- clinical toxicology 
findings for Spi[INVESTIGATOR_510448].Eligibility criteria have been selected to ensure only 
appropriate participants are included in the study and 
study procedures are in place to evaluate this risk 
ie,physical examination. AEs will be closely 
monitored.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 222.3.2. Benefit Assessment
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coat ed tablets are not expected to provide any  
clinical benefit to healthy participants.
2.3.3. Overall Benefit /Risk Conclusion
Spi[INVESTIGATOR_8407]/Hy
drochlorothiazide film coated tablets are not expected to provide any  
clinical benefit to healthy participants. This study is designed primaril y to generate PK, 
safety and tolerability  data of spi[INVESTIGATOR_510449]/Hy drochlorothiazide 25 mg/25 mg strength film coated tablets 
manufactured at Neolpharma .
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Prim ary: Prim ary:
To demonstrate bioequivalence betw een 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 
25mg/25 mg film coated tablets manufactured 
at the proposed site (Neolpharma) vs 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 
25mg/25 mg film coated tablets manufactured 
at current site (Viatris) under fasting conditions 
in healthy adult participants.Cmax, AUC inf(or AUC lastif AUC infcannot be 
reliably estimated) of Spi[INVESTIGATOR_510450].
Secondary: Secondary:
To further characterize PK of Spi[INVESTIGATOR_510451].
To evaluate the safety and tolerability of 
Spi[INVESTIGATOR_8407]/ Hydrochlorothiazide film 
coated tablets.t½(if data permit) and T maxof Spi[INVESTIGATOR_510451].
AEs, clinical laboratory tests, vital signs, and 
ECGs.
4.STUDY DESIGN
4.1.Overall Design
This will be an open -label, randomized, single- dose, 2 -treatment, 2 -period, 2- sequence, 
crossover stud y in adult healthy male and/or female participants. Approximately  
40participant s will be enrolled in the study  ( 20in each treatment sequence). Dropouts for 
non-safet y reasons or non- evaluable participants may  be replaced at the discretion of the 
sponsor and investigator. Screening evaluation will occur within [ADDRESS_660030] 
dose of study  medicati on. Participant s will be assigned to 1 of the following 2 sequences 
according to a computer -generated randomization schedule.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 23Table 3. Treatment Sequence
Sequence Number of Participants Period [ADDRESS_660031] 4days Treatment B
2 20 Treatment B Treatment A
Treatment A: Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 25 mg/25 mg film coated tablets manufactured at the 
current site (Viatris) under fasting conditions.
Treatment B: Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 25 mg/25 mg film coated tablets manufactured at the 
proposed site (Neolpharma) under fasting conditions.
There will be a minimum 4-day washout period between successive doses (ie, administration 
of subsequent doses of s tudy medication will not occur until at least 4days after the previous 
dose of study  medication).
Screening evaluation will occur within [ADDRESS_660032] day  of dosing (Da y 1) in each period.
Participant s will be admitted to the CRU on Day  -
1 and will remain confined in the CRU 
from Period 1 through Period 2 until the collectio n of the 48
-hour PK sample making it a 
total of 8 days and 7nights including Day  -1.The washout period between the 2successive 
dosing ’swill be at least 4 day s(96 hours) .
On Day  [ADDRESS_660033] as 
per randomization schedule . 
Study  treatments will be administered with 240 mL  of ambient 
temperature water under fasted conditions (overnight fast and no food until 4 hours after 
dosing). W ater will be allowed without restriction until 1 hour prior to dosing andmay be 
consumed without restriction beginning 1 hour after dosing.
Blood s amples for the analy sis of spi[INVESTIGATOR_510452] (immediatel y prior to dosing) and postdose as outlined in the S chedule of Activ ities.
Tolerability  
and safety  will be assessed for all treatments by  [CONTACT_42466].
4.2.Scientific Rationale for Study Design
Currently  Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets are manufactured at 
Viatris. PGS intends to transfer drug product manufacturing operations for 
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets from the currentl y registered Viatris 
manufacturing site to the proposed Neolpharma manufacturing site. The f2could not be 
calculated due to high %RSD valu es (high variability ). Bootstrap f2analy sis was performed, 
and the similarity  factor calculated was outside of acceptable range. The comparative 
dissolution profile data between existing site and proposed new site when tested in release 
media failed as th e similarity  factor (f2) calculated did not pass the criterion (f2 value being 
<
50) for both Spi[INVESTIGATOR_74963] h ydrochlorothiazide in release media tested. Therefore, this 
BE stud y is being conducted to qualify the manufacturing site transfer, and the ass ociated 
process changes, b y demonstrating BE between Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film 
coated tablets manufactured at the proposed site ( Neolpharma ) versus exist ing site ( Viatris ).

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 244.2.1. Choice of Contraception/Barrier Requirements 
Spi[INVESTIGATOR_8407]/Hy drochl orothiazide is known to cause risk for severe manifestations of 
developmental toxicity  in humans or suspected on the basis of the nonclinical 
studies .Therefore, the use of a highl y effective method of contraception is required (see 
Appendix 4
).
Nonclinical studies suggest risk for severe manifestations of developmental toxicity  at 
relevant clinical exposures for Spi[INVESTIGATOR_8407]/Hydrochlorothiazide. Therefore, the use of a 
highl y effective method of contraception is required (see Appendix 4 ).
Studies to evaluate the development altoxicit y of Spi[INVESTIGATOR_8407]/Hy drochlorothiazide have 
not been conducted. Therefore, the use of a highl y effective met hod of contraception is 
required (see Appendix 4 ).
4.3.Justification for Dose
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets have a dose strength equivalent to 
25mg/25 mg respectively .Since this is the only dose that will be transferred from Viatris to 
Neolpharma for spi[INVESTIGATOR_74963] h ydrochlorothiazide, a BE stud y will be conducted for 
the 25 mg/[ADDRESS_660034] participant s for whom participation in the study  is consider ed 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol .
Prospective approval of protocol deviations to recruitment and enrollment criter ia,also 
known as protocol waivers or exemptions, is not permitted .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 255.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1.Male and female participants must be 18to 75 y ears of age, inclusive, at the time o f 
signing the ICD .
Refer to 
Appendix 4 for reproductive criteria for male ( Section 10.4.1) and female 
(Section 10.4.2) participants.
Other Inclu sion Criteria :
2.BMI of 16-
32 kg/m2; and a total body  weight >50 kg (110 lb).
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedure s.
4. Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the I CD and in 
this protocol.
5.2.
Exclusion Criteria
Participants are excluded from th e study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (includi ng drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing ).
Any condition possibly  affecting drug absorption (eg, gastrectomy , 
cholecy stectom y).
History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, 
HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
2.Any medical or ps ychiatric condition including recent (within the past year) or active 
suicidal ideation /behavior or laboratory  abnormality that may  increase the risk of
study  participation or , in the 
investigator’s judgment, make the participant 
inappropriate for the study .
Prior/Concomitant Therapy:
3.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 26intervention. ( Refer to Section 6.9 Prior and Concomitant Therap y for additional 
details)
.
4.Current use of any prohibited concomitant medication(s) or participant unwilling or 
unable to use a required concomitant medication(s). Refer to Section 6.9Prior and 
Concomitant Therap y.
Prior/Concurrent Clinical Study Experience:
5.Previous administration with an investigational product (drug or vaccine) w ithin 
30days (or as determined by  [CONTACT_19970]) or [ADDRESS_660035] 
dose of study  intervention used in this study  (whichever is longer). Participation in 
studies of other investigational products (drug or vaccine) at an y time duri ng their 
participation in this study .
Diagnostic Assessments:
6.A positive urine drug test . Asingle repeat for positive drug screen may be allowed.
7.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_660036]. If sy stolic BP is ≥ 140or 150 mmHg (based on age ) or
diastolic ≥90mmHg, the BP should be repeated 2more times and the average of the 
3BP values should be used to determine the participant’s eligibility . 
8.Hepatic d ysfunction defined as:
Total bilirubin ≥1.5 × ULN (For Gilbert’s sy ndrome, direct bilirubin >ULN is 
exclusionary )
AST ≥1.5 × ULN
ALT ≥1.5 × ULN
9.Baseline standard 12- lead ECG that demonstrates clinically  relevant abnormalities 
that may  affect participant safet y or interpretation of stu dy results (eg, QTcF >450 
ms). If QTcF exceeds 450 ms, the ECG should be repeated twice and the average of 
the 3 QTcF values used to determine the participant’s eligibility . Computer -
interpreted ECGs should be overread b y a physician experienced in reading ECGs 
before excluding a participant.
Other Exclusion Criteria:
10.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours . As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit= 8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spi[INVESTIGATOR_17040] ,or 3ounces (90 mL) of wine).

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 2711. Blood donation (excluding plasma donations) of appr oximately  1pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_660037] of the study  and their family  
members.
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Contraception
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contr aception methods (see Appendix 4 ,
Section 10.4.4) and will confirm that the participant has been instructed in its consistent and 
correct use. The investigator or designee will advise the participant to seek advice about the 
donation and cry opreservation of germ cells prior to the start of study  intervention, if 
applicable .
At time points indicated in SoA, the investigator or designee will inform the participant of 
the need to use 
highl yeffective contraception consi stently  and correctly  and document the 
conversation and the participant’s affirmation in the participant’s chart. Participants need to 
affirm their consistent and correct use of at least [ADDRESS_660038] the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol -specified method, including if the participant will no longer use abstinence 
as the selected contraception method, or if pregnancy is known or suspected in the participant 
or partner.
5.3.2. Meals and Dietary Restrictions
Participant s must abstain from a ll food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PK sample.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 28Water is permitted until 1 hour prior to study  intervention administration
.Water may  
be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 
(except grapefruit or grapefruit- related citrus fruit juices—see below) may  be 
consumed with meals and the evening snack .
Lunch will be provided approximately  4hours after dosing .
Dinner will be provided approximately  9to 10 hours after dosing.
An evening snack may be permitted .
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_660039] 
dose of study  intervention until collection of the final PK blood sample. 
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat ,and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.3. Caffeine, Alcohol, and Tobacco
Participant s will abstain from caffeine -containing products for [ADDRESS_660040]
e of each study  period. 
Participant s will abstain from alcohol for [ADDRESS_660041] at the discretion of the investigator.
Participant s will abstain from the use of tobacco -or nicotine -containing products for 
24 hours prior to dosing and during confinement in the C RU.
Smoking may  be allowed according to CRU practices. Smoking will not be permitted 
during frequent sampling procedures, and will not be permitted within 2 hours prior 
to any  vital sign orECG assessments. Smoking will also not be permitted 2 hours 
before and 2 hours following an y dose of study  intervention .
5.3.4. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walk ing at a normal pace will be permitted;
In order to standardize the conditions on PKsampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages oth er than water during the first 
4 hours after dosing
.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 295.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain a s 
source and are not reported on the CRF.
Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened. 
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  interventions are all prespecified investigational a nd medical devices, and other 
interventions (eg, surgical and behavioral) intended to be administered to the study  
participants during the study conduct.
For the purposes of this protocol, study  intervention refers to
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablets.
6.1.Study Intervention(s) Administered
Study Intervention(s)
Intervention Name [CONTACT_84899][INVESTIGATOR_8407]/Hydrochlorothiazide Spi[INVESTIGATOR_8407]/Hydrochlorothiazide
Type Drug Drug
Use Reference Product Test Product
IMP or NIMP/AxMP NIMP IMP
Dose Form ulation Film Coated Tablets Film Coated Tablets
Unit Dose Strength(s) 25 mg/25 mg 25 mg/25 mg
Dosage Level(s) Single dose Single dose
Route of 
AdministrationOral Oral
Sourcing Provided centrally by [CONTACT_510467]. 
Each container will be labeled as 
required per country requirement.Study intervention will be provided in 
unit dose containers as unblinded. Each 
container will be labeled as required per 
country requirement.
SRSD Package Insert Package Insert
Current Name(s) Spi[INVESTIGATOR_8407]/Hydrochlorothiazide Spi[INVESTIGATOR_8407]/Hydrochlorothiazide

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 30Study Arm(s)
Arm  Title Treatment A (Reference ) Treatment B ( Test)
Arm  Description Participants will receive 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 
25mg/25 mg film coated tablet 
manufactured at Viatris on Day 1 of 
each treatment period.Participants will receive 
Spi[INVESTIGATOR_8407]/Hydrochlorothiazide 
25mg/25 mg film coated tablet 
manufactured at Neolpharma on 
Day 1 of each treatment period.
Pi[INVESTIGATOR_510453]/BE study film coated tablets will be supplied to the CRU in multidose labeled 
containers (in sufficient number to allow unopened containers to be kept as retains).
6.1.1. Administration
Following an overnight fast of at least 10 hours, participant s will receive study  intervention
at approximately  0800 hours (plus or minus 2 hours). Investigator site personnel will 
administer study  intervention during each period with ambient temperature water to a total 
volume of approximately 240mL.
Participant s will swallow the study  intervention whole, and will not manipulate or chew the 
study  intervention prior to swallowing.
In order to standardize the conditions on PKsampling day s, all participant s will be required 
to refrain from ly ing down (except when required for BP , 
pulse rate , and ECG 
measurements), eating, and drinking beverages other than water during the first 4 hours after 
dosing.
Administration of study  intervention(s) at the site will be performed b y an appropriatel y 
qualified and trained member of the stud y staff as allowed b y local, state, and institutional 
guidance.
Following administration of study  interventio n(s)at the site , participants will be observed for 
[ADDRESS_660042] confirm that appropriate conditions (eg, 
temperature) 
have been maintained during transit for all study  intervention sreceived 
and an y discrepancies are reported and resolved before use of the stud y intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply , prepare, and/ or administer study  intervention.
3.All study  interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 31storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented upon 
return to business.
4.Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with actions taken. The site should activel y 
pursue options for returning the stud y intervention to the labeled 
storage conditi ons, 
as soon as possible. Once an excursion is identified, the study  intervention must be 
quarantined and not used until [COMPANY_007] provides permission to use the study  
intervention. Specific details regarding the excursion definition and information to
report for each excursion will be provided to the site in the I PM.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
6.Study  interventions should be stored in their original containers.
7.The investigator, i nstitution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study  intervention accountability , 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition records), such as the IPAL or sponsor -approved equivalent. All study  
interventions will be accounted for using a stud y intervention accountability 
form/record.
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the I PM. All destruction must be adequatel y 
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any special instructions 
provided b y [COMPANY_007].
9.All pi[INVESTIGATOR_510453]/BE retains should be stored by  [CONTACT_510468] a 
third- party vendor. Sample retention is the responsibility  of the entity  performing the 
BA/BE study .
Upon identification of a produc t complaint, notify the sponsor w ithin 1 business day  of 
discovery  as described in the I PM.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administr ation or dispensing to the participant by [CONTACT_216479]. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 32participant ,in accordance with this protocol. L ocal health authorit y regulations or 
investigator site guidelines may  use alternative terms for these activities.
Tablets will be prepared at the CRU in the individual dosing containers b y 2operators, 1 of 
whom is an appropriatel y qua lified and experienced member of the stud y staff (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist). 
The tablets will be provided in unit dose containers and labeled in accordance with [COMPANY_007] 
regulations and the clinical site’s labeling requirements.
6.3.Assignment to Study In tervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participant s are 
enrolled.
The investigator will assign participant numbers to the participant s as they  are screened for 
the study . [COMPANY_007] will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will rece ive the stud y treatment regimen 
assigned to the corresponding randomization number.
6.4.Blinding
This is an open -label study .
As this is an open -label study ,the sponsor may  conduct reviews of the data during the course 
of the study  for the purpose of safety  assessment, facilitating dose
-escalation decisions, 
facilitating PK/PD modeling, and/or supporting clinical development .
6.5. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigat or or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF. 
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study  intervention was ingested.
6.6. Dose Modification
Dose modification is not allowed in this single dose study .
6.7.Continued Access to Study Intervention A fter the End of the Study
Nostudy intervention will be provided to participants at the end of their study  participation.
6.8.Treatment of Overdose
For this study , any dose of Spi[INVESTIGATOR_8407]/Hydrochlorothiazide greater than 25 mg/25 mg 
within a 24- hour time period will be considered an overdose.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 33There is no specific treatment for an overdose.
In the event of an overdose, the investigator/treating ph ysician should:
1.Contact [CONTACT_219876] 24 hours.
2.Closely  monitor the participant for an y AEs/SAE s and laboratory  abnormalities as 
medically  appropriate and follow up 
until resolution, stabilization, the event is 
otherwise explained, or the participant is l ost to follow -up (as defined in Section 7.3).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to [COMPANY_007] 
Safety  only when associated with a nSAE .
5.Obtain a blood sample for PK anal ysis within 3days from the date of the last dose of 
study  intervention if requested by  [CONTACT_219877] (determined on a 
case-by-case basis ).
6.9.Prior and Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives ( whichever is longer) prior to the first dose of study
 
intervention. L imited use of nonprescriptio n medications that are not believed to affect 
participant safety  or the overall results of the study may be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤1g/day .
Hormonal contracept ives that meet the requirements of this study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
All concomitant treatments taken during the study  must be recorded with indication, dail y 
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within [ADDRESS_660043] dose of study  intervention 
will be documented as concomitant treatments.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Since this is a single -dose stu dy, this section is not applicable.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 347.1.1. Potential Cases of Acute Kidney Injury
Participants exposed to IMP demonstrating transient or sustained increase in Screat (with 
decrease in Screat -based eGFR) require expedited evaluation to differentiate AKI from DICI.
DICI is defined as transporter -mediated effect related to altered renal tubular creatinine 
handling without histological injury .
AKI may be due to one or more t ypes of injury, including DIKI. Differentiation of DIKI 
from other causes of AKI and from DICI may  require clinical, radiographic, histopathologic, 
and laboratory  assessments, as well as nephrology  consultation.
Follow -up Assess ments
The participant should return to the site for evaluation as soon as possible, preferabl y within 
48 hours of awareness of the abnormal results.
Evaluation should include phy sical examination, laboratory  tests, detailed medical and 
surgical history , review of all medications (including recreational drugs and supplements 
[herbal]), family  history , sexual history , travel history , blood transfusion, and potential 
occupational exposure to chemicals.
Laboratory  assessments should include simultaneous serum c ystatin C (Scys) and serum 
creatinine (Screat) tests. Estimates of eGFR and Screat -based eGFR and combined Screat
-
Scys-based eGFR should also be derived using the appropriate equation described in 
Appendix 7 .
Assessments of urine albumin -to-creatinine ratio or urine volume may  also be performed as 
appropriate.
Differentiating Acute Kidney Injury from DICI
A confirmed Screat increase is defined as:
(i) ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours OR
(ii) confirmed Screat increase ≥1.5 times baseline (known or suspected to have occurred 
within the prior 7 day s).
Based on the assessments performed, suspected AKI (including DIKI) may be differentiated 
from DICI as follows.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 35Adult participants
AKI (including DIKI)
Any one of the belowDICI
Scys & Screat Simultaneous, confirmed serum cystatin 
C (Scys) increase and confirmed Screat 
increaseConfirmed Screat increase without 
confirmed increase in reflex Scys
AND
Confirmed Screat -based eGFR 
decrease w ithout confirmed combined 
Screat -Scys -based eGFR decrease.eGFR Decrease in Screat -based eGFR and 
combined Screat -Scys -based eGFR (when 
available)
Albuminuria or 
proteinuriaConfirmed albuminuria increase (see 
Appendix 7 for Grades A1 to A3 
quantitation)
Urine volume Urine volume <0.5 mL/kg/h for 6 
consecutive hours
Regardless of the presence or absence of increase in Screat, DIKI and other causes of AKI 
may be suspected if either there is (i) new -onset or worsening albuminuria or proteinuria are 
detected.
All confirmed cases of clinically  relevant decrease in kidney  function should be considered 
potential cases of DIKI if no other reason for the kidney  function abnormalities has been 
found.
7.1.2. ECG Changes
A participant who meets the bulleted criteria based on the average of triplicate ECG readings 
will be withdrawn from the study  intervention.
QTcF >500 ms.
Change from baseline: QTcF >60 ms and QTcF >450 ms.
If a clinically  significant finding is identified (including, but not limited to, changes from 
baseline in Q TcFafter enrollment), the investigator or qualified designee will dete rmine if 
the participant can continue in the study  and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. An y 
new clinicall y relevant finding should be reported as an AE.
7.1.3. Pregnancy
In the case of a positive confirmed pregnancy , the participant will be withdrawn from the 
study .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 367.1.4. COVID -19
If a participant has COVID -19 during the study , this should be reported as an AE or SAE (as 
appropriate) and appropriate medical intervention provided. Study  treatment should continue 
unless the investigator/treating ph ysician is concerned about the safet y of the participant, in 
which case temporary  or permanent discontinuation may be required.
It is recommended that the investigator discuss temporary  or permanent discontinuation of 
study  intervention with the study  medical monitor.
7.2.Participant Discontinuation/ Withdrawal
From the Study
A participant may  withdraw from the study  at an y time at their own request . Reasons for 
discontinuation from the study  include the following : safet y, behavioral, compliance, or 
administrative reasons.
At the time of discontinuing from the stud y, if possibl e, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuati onvisit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.
The participant will be permanentl y discontinued from the study i ntervention and the study  at 
that time.
If a participant withdraws from the study , they may request destruction of any  remaining 
samples taken and not tested, and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.[ADDRESS_660044] 
with them or persons previously  authorized by  [CONTACT_104140]. 
Participant s should notify  the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by
 [CONTACT_093], as to whether the withdrawal is only  from 
further receipt of study  intervention or also from study  procedures and/or posttreatment st udy 
follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 37the participant is alive or dead) is being measured, publicly  available information should be 
used to determine vital status only  as appropriately  directed in a ccordance with local law.
7.3.Lost to 
Follow -Up
A participant will be considered lost to follow- up if the participant repeatedly  fails to return 
for scheduled visits and is unable to be contact[CONTACT_17066].
The following actions must be taken if a part icipant fails to return to the clinic for /attend a 
required stud y visit:
The site must attempt to contact [CONTACT_14315] . Counsel the participant on the importance of maintaining the 
assigned visit sched ule and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telepho ne 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachable, the participant will be considered 
to have withdrawn from the study .
8.STUDY ASSESSMENTS AND PROCEDURES
8.1.Administrative Procedures
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an ystudy -specific procedures.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all par ticipants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 38investigator will document the reason for the missed test and an y corrective and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participant s in this study  is approximately  
290mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provide d the total 
volume taken during the study  does not exceed 550 mL during an y period of 56 consecutive 
days.
To prepare for stud y participation, participants will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy  sectio ns of the protocol.
8.2.Efficacy Assessments
Efficacy  parameters are not evaluated in this study .
8.3.Safety Assessments
Planned time points for all safety  assessments are provided in the 
SoA.Unscheduled safety
measurements may  be obtained at any  time during the study  to assess any  perceived safety  
issues.
8.3.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and participant -reported s ymptoms.
Physical examina tions may  be conducted by  a ph ysician, trained ph ysician ’s assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participant s must remove shoes, bulky  layers of clothing, and jackets s
othat only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight.
Physical examination findings collected during the study  will be considered source record 
and will not be required to be reported, unless otherwise noted. An y untoward ph ysical 
examination findings that are identified during the active collection period and meet the 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 39definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.
4.1to 8.4.3.
8.3.2. Vital Signs
[IP_ADDRESS]. Blood Pressure and Pulse Rate
Supi[INVESTIGATOR_78235] ’s arm supported at the level of the heart, and 
recorded to the nearest mm Hgafter approximately  5minutes of rest . The same arm 
(preferabl y the dominant arm) will be used throughout the study. 
Participant s should be 
instructed not to speak during measurements.
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery
 for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BPand pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
Any untoward vital sign findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3) must be reported according to the 
processes in Sections 8.4.[ADDRESS_660045] 5 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥60 msfrom the baseline andis >450 ms; or b) an 
absolute QT value is ≥500msfor an y scheduled ECG. If either of these conditions occurs, 
then [ADDRESS_660046] hourl y until QTc values from 
2successive ECGs fall below the threshold value that triggered the repeat measurement.
If a) a postdose QTcF interval remains 
≥60msfrom the baseline and is >450 ms; or b) an 
absolute QT value is ≥500 ms for an y scheduled ECG for greater than 4 hours (or sooner ,at 
the discretion of the investigator) ;or c) QTcFvalue get progressively  longer, the participant
should undergo continuous ECG monitoring. A cardiologist should be consulted if QTc F
values do not return to less than the criteria listed above after 8 hours of monitoring (or 
sooner ,at the discretion of the investigator).

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 40In some cases, it may  be appro priate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider
’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 8.
8.3.4. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_660047] findings are those that are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259] ’s condition.
All laboratory  tests with values consid ered clinically  significant and abnormal during 
participation in the study  or within [ADDRESS_660048] dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  signific ant b y the investigator or study  medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -up assessments in the event of potential 
DILI .
See Appendix [ADDRESS_660049] abnormalities.
[IP_ADDRESS].
Alternative Facilities for Clinical Safety Laboratory Assessment
Not applicable .
8.3.5. Pregnancy Testing
A urine or serum pregnancy  test is required at screening. Following screening, pregnancy  
tests may  be urine or serum tests, andmust have a sensitivity  of at least 25 mIU/mL. 
Pregnancy  tests will be performed in WOCBP at the times listed in the SoA . Following a 
negative pregnancy  test result at screening, approp riate contraception must be commenced 
and a second negative pregnancy  test result will be required at the baseline visit prior 
to 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 41starting the Spi[INVESTIGATOR_8407]/Hy drochlorothiazide film coated tablet . Pregnancy
 tests will also 
be done whenever 1 menstrual cy cle is missed during the active treatment period (or when 
potential pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  
also be repeated if requested by  [CONTACT_1202]/E Cs or if required by [CONTACT_427]. If a urine test 
cannot be c onfirmed as negative (eg, an ambiguous result), a serum pregnancy  test is 
required. In such cases, the participant must be excluded if the serum pregnancy  result is 
positive .
8.4.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definition s of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant ’s legally  
authorized representative), or they  may  arise from clinical findings of the i nvestigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and an y qualified designees are responsible for detecting, documenting, a nd 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the partic ipant to discontinue 
thestudy (seeSection 
7.1).
During the active collection period as described in Section 8.4.1, e achparticipant will be 
questioned about the occurrence of A Es in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -up 
information in an expedited fashion.
8.4.1.
Time Period and Frequency for C ollecting AE and SAE Inf ormation
The time period for actively  eliciting and collecting A Es and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before undergoing an y stud y-related procedure and/or receiving study  
intervention ), through and including a minimum of [ADDRESS_660050] ion period, 
follow -up by  [CONTACT_227985] a level acceptable to the investigator and [COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 42If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues study because of an AE 
or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the CT 
SAE Report Form.
Investigators are not obligated to activel y seek information on A
Esor SAE safter the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has concluded stud yparticipation , and they
consider the event to be reasonabl y related to the study  intervent ion, the investigator must 
promptly  
report the SAE to [COMPANY_007] using the CT SAE Report Form .
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period 
as described in 
Section 8.4.[ADDRESS_660051] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24hours of it s being available.
[IP_ADDRESS]. Recording Nonserious A E
s and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.[ADDRESS_660052] 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.4.2. Method of Detecting AE s and SAEs
The method of recording, evaluating, and assessing causality  of A Esand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AE s and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.4.3. Follow -
Up of A Es and SAEs
After the initial AE or SAE report, the i nvestigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 43obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Section 7.3 ).
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possibl e causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety .
Further information on follow -up procedures is provi dedin Appendix 3.
8.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n
SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulato ry authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, a nd 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure in
clude healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include EDP, EDB , and occupational exposure.
Any such e xposure s to the study  intervention under study  are reportable to [COMPANY_007] Safety  
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 44A male participant who is receiving or has discontinued study  intervention
insemin ates a female partner .
A female nonparticipant is found to be pregnant while being exposed or having been 
exposed to study  intervention because of environmental exposure. Below are 
examples of environmental EDP :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  
[CONTACT_78262], inhalation, or skin 
contact .
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  [CONTACT_78262], inhalation, or ski n contact [CONTACT_336270] .
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy).
If EDP occurs in a participant
/participant’s partner , the investigator must report this 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form regardless of whether an SAE has occurred. Details of the pregnancy will be 
collected after the start of study intervention and until [ADDRESS_660053] dose .
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form . Since the exposure 
information does not pertain to the participant enrolled in the study , the information is 
notrecorded on a CRF; however, a cop y of the completed report is maintained in the 
investigator site file .
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial report . In the case of a live birth, the structural integrity  of the neonate 
can be assessed at the time of birth . In the event of a termination, the reason(s) for 
termination should be specified and, if clinicall y possible, the structural integrit y of the 
terminated fetus should be assessed b y gross visual inspection (unless pre -procedure test 
findings are conclusiv e for a congenital anomal y and the findings are reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 45for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion should be reported 
as an SAE ;
Neonatal deaths that occur within [ADDRESS_660054] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -
up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if: 
A female partic ipant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study  intervention (ie, environmental exposure). An example of 
environmental EDB is a female famil y member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study  intervention by  
[CONTACT_78262], inhalation, or skin contact . 
The investigator must report EDB to Pfize r Safety  within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the CT SAE Report Form . When 
EDB occurs in the setting of environmental exposure, 
the exposure information does no t pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy  of the completed report is 
maintained in the investigator site file.
An EDB report is not created when a [COMPANY_007] drug specificall y approved for use in 
breastfeeding women (eg, vitamins) is administered in accord ance with authorized use. 
However, if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the EDB .
[IP_ADDRESS]. Occupational Exposure
The investigator must report 
any instance of occupational exposure to [COMPANY_007] Safet y within 
24 hours of the investigator’s awareness using the CT SAE Report Form regardless of 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 46whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed report ismaintained in the investigator site file.
8.4.6.
Cardiovascular and Death Events
Not applicable .
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AE s 
or SAEs
Not applicable.
8.4.8. Adverse Events of Special Interest
AESI sare examined as part of routine safet y data review procedures throughout the clinical 
trial and as part of signal detection proce sses. Should an aggregate analy sis indicate that 
these prespecified events occur more frequentl y than expected, eg, based on epi[INVESTIGATOR_227924], literature, or other data, then this will be submitted and reported in accordance with 
[COMPANY_007]’s safet y report ing requirements. Aggregate anal yses of safet y data will be performed 
on a regular basis per internal SOP. 
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.4.[ADDRESS_660055] SAE Report Form .
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable b ecause efficacy  is not expected in the study  population.
8.4.9. Medical Device Deficiencies
Not applicable.
8.4.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Medication errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly  if associated with an 
SAE

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 47Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], such medication errors occurri
ng to a study  participant are recorded on the 
medication error page of the CRF, which is a specific version of the AE page and, if 
applicable, an y associated serious and nonserious AE(s), are recorded on the AE page of the 
CRF.
In the event of a medicatio n dosing error, the sponsor should be notified within [ADDRESS_660056] SAE Report 
Form only when associated with an SAE.
8.5.Pharmacokinetics
Blood samples will be collected for measurement of plasma concentrations of HCTZ and 
Spi[INVESTIGATOR_510454].Instructions for the collection and handling of 
biological samples will be provided in the laboratory  manual or by  [CONTACT_456]. The actual 
date and time (24 -hour clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of
samples up to and including 10 hours after dose administration that are obtained within 10% 
of the nominal time relative to dosing (eg, within 6 minutes of a 60 -minute sample) will not 
be captured as a protocol deviation, as long as the exact time of the collection is noted on the 
source document and the CRF. Collection of samples more than 10 hours after dose
administration that are obtained ≤1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. This protocol deviation window does not apply  to samples 
to be collected more than 10 hours after dose a dministration at outpatient/follow -up visits 
with visit windows.
Samples will be used to evaluate the PK of spi[INVESTIGATOR_510448] . Samples collected for 
analyses of spi[INVESTIGATOR_510455] y or efficacy aspects related to concerns arising during or after the study, for metabolite 
identification and/or evaluation of the bioanal ytical method, or for other internal exploratory  
purposes. The exploratory  results may  not be reported in the CSR .
Genetic anal yses will not be performed on these plasma samples. Participant confidentiality  
will be maintained.
Samples collected for measurement of plasma concent rations of spi[INVESTIGATOR_510456] a validated anal ytical metho d in compliance with applicable SOPs.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 48The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample i ntegrity .Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised.
8.6.Genetics
8.6.1. Specified Genetics
Specified g enetic anal yses are not evaluated in this study .
8.6.2. Retained Research Samples for Genetics
A 4-mL blood sample optimized for DNA isola tion Prep D1 will be collected according to 
the SoA ,as local regulations and I RBs/E Cs allow.
Retained Research Samples may be used for research related to thestudy  
intervention (s). 
Genes and other analy tes (eg ,proteins, RNA, nondrug metabolites) may  be studied using the 
retained samples.
See Appendix 5 for information regarding genetic research.
Details on processes for 
collection and shipment of these samples can be found in the la b manual .
8.7.Biomarkers
Biomarkers are not evaluated in this study .
8.8.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.9.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDERATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in the 
SAP, which will be maintained by  [CONTACT_456]. 
The SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 499.1.Statistical Hypothesis
The alternative hy pothesis of BE (H1: L<=T-R<=
U), and the null h ypothesis of 
inequivalence (H o: T-R<Lor T-R>U) can be expressed as the following 2separate 
1-sided hy potheses:
HoA: T-R<L
H1A: L<=T-R
HoB: T-R>U
H1B: T-R<= U
Where Tand Rrepresent the average BAon a log scale for the Test and Reference 
products respectivel y and [ L, 
U] defines the BE range.
BEof the Test treatment to Reference treatment will be concluded if the 90% CIs for the 
ratios of adjusted geometric means for both spi[INVESTIGATOR_74963] h ydrochlorothiazide AUC inf
and C max fall entirely
 within the acceptance region of (80%, 125%) .
9.2.Analysis Sets
For purposes of analy sis, the follow ing analysis sets are defined:
Partici pant Analysis 
SetDescription
Enrolled “Enrolled ”means a participant ’s, or their legally  authorized 
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process and 
randomization. 
Full a nalysis set Example: All participants randomly  assigned to study  
intervention and who take at least 1dose of stud y intervention .
Safety analysis set All participants randomly  assigned to study  intervention and 
who take at least [ADDRESS_660057] they actually  received.
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
PKparameters will be derived from the concentration -time profiles as shown in Table 4. 
Actual PK sampling times will be used in the derivation of PK parameters.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 50Table 4. PK Parameters
Param eter Definition Method of Determ ination
AUC last Area under the plasma concentration -time 
profile from time [ADDRESS_660058] 
quantifiable concentration (C last)Linear -log trapezoidal method
AUC infaArea under the plasma concentration -time 
profile from time [ADDRESS_660059]+ (C last*/k el),
where C last* is the predicted plasma 
concentration at the last quantifiable time point 
estimated from the log -linear regression 
analysis.
Cmax Maximum plasma concentration Observed directly from data
Tmax Time for C max Observed directly from data as time of first 
occurrence
t½aTerm inal elimination half -life Ln(2)/k el,
where k elis the terminal phase rate constant 
calculated by a linear regression of the log 
linear concentration -time curve. Only those 
data points judged to describe the terminal 
log-linear decline will be used in the 
regression.
a.If data permits.
Actual PK sampling times will be used in the derivation of PK parameters. I n the case that 
actual PK sampling times are not available, nominal PK sampling time will be used in the 
derivation of PK parameters.
9.3.1. General Considerations
Not applicable.
9.3.2. Primary Endpoint(s) Analysis
Pharmacokinetic and statistical analy sis will be performed for spi[INVESTIGATOR_510457] .
Natural log transformed PK parameters (C max, AUC inf(or AUC lastif AUC infcannot be 
reliably estimated) ) will be anal yzed using a mixed effect model with sequence, period and 
treatment as fixed effects and participant within sequence as a random effect. Estimates of 
the adjusted mean differences ( Test/ Reference ) and the corresponding 90% CI s will be 
obtained from the model. The adjusted mean differences and the 90% CIs for the differences 
will be exponentiated to provide estimates of the ratio of adjusted geometric means ( Test/ 
Reference ) and the 90% CI s for the ratio s.
For bioequivalence assement of Spi[INVESTIGATOR_8407]/Hy drochlorothiazide 25/25 mg film coated 
tablets between proposed site ( Neolpharma ) and current site ( Viatris ), bioequivalence of the 
Test treatment (Treatment B) relative to Reference treatment (Treatment A) will be 
concluded if the 90% confidence intervals for the ratio of adjusted geometric means of Test 
treatment (Treatment B) relative to Reference treatment (Treatment A) for Cmax, AUC inf(or 
AUC lastif AUC infcannot be reliabl y estimated) fall wholly  within (80%, 125%).

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 519.3.3. Secondary Endpoint(s) Analysis
The secondary  PK parameters like T maxand t½would be derived from the concentration- time 
profiles. 
AUC inf, area under the plasma concentration- time profile from time [ADDRESS_660060]+ (C last*/k el), where C last* is the predicted plasma 
concentration at the last quantifiable time point estimated from the log -linear regression 
analysis. C maxis the maximum plasma concentration observed directly  from the data. t½is the 
terminal elimination half
-life calculated from Ln(2)/k el, where k elis the terminal phase rate 
constant calculated b y a linear regression of the log linear concentration -time curve. Onl y 
those data points judged to describe the terminal log- linear decline will be used in the 
regression.
The PK parameters AUC last, AUC inf, Cmax, Tmax, and t ½will be summarized descriptivel y by 
[CONTACT_110367]. For AUC inf, AUC last, and C maxparameters, individual data and 
geometric mean will be plotted with box p lots by  [CONTACT_216481]. 
Plasma concentration data will be listed and summarized descriptivel y by [CONTACT_110368], PK 
sampling time and treatment. I ndividual participant and summary  profiles (mean and median) 
of the plasma concentration- ti
me data will be plotted against anal yte by [CONTACT_3148]. Mean and 
median profiles will be presented on both linear- linear and log -linear scales. For summary  
statistics and summary  (mean and median) plots by  [CONTACT_31065], the nominal PK sampling 
time will be used. For individual participant plots by  [CONTACT_5586], the actual PK sampling time will 
be used.
9.3.4. Safety Analyses
All safet y anal yses will be performed on the s afety population.
AEs, ECGs, 
BP, pulse rate , and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participant s. An y clinical 
laboratory , ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described. Safet y data will be presented in tabular and/or graphical format an d summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination and neurological examination information, as 
applicable, collected during the course of the study, will be considered source data and will 
not be required to be reported, unless otherwise noted. However, an y untoward findings 
identified on phy sical and/or neurological examinations conducted during the active 
collection period will be captured as A
Es, if those findings meet the definition of an AE. 
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be considered source data, and will not be required to be 
reported, unless otherwise noted. Demographic data collected at screening will be reported.
9.3.5. Other Analyses
Not applicable.
9.4.Interim Analyses
No interim anal ysis will be conducted for this study .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 529.5.Sample Size Determination
A sample size of 38 evaluable participants will provide ≥99.9% and 91.0% power that the 
90% CI for the ratio of Test to Reference treatment for C maxandAUC inf(or AUC lastif AUC inf
cannot be reliably  estimated) of spi[INVESTIGATOR_8407], respectively , will lie within the acceptance 
region of (80%, 125%). Additionally , it will provide 
≥99.6% and ≥99.0% power that the 90% 
CIs for the ratios of Test to Reference treatment for AUC infand C maxof HCTZ will lie within 
the acceptance region of (80%, 125%). Consequently , this study  will have approximately  
90% overall power to demonstrate BE of the Test treatment to the Reference treatment (ie, 
equivalence for both AUC and C max) of both spi[INVESTIGATOR_510448] , where overall powe r 
for the stud y is based on the product of the individual powers of the parameters of interest.
These estimates are based on the assumption that the true ratio between Test and Reference 
treatments for both AUC infand C maxis 0.[ADDRESS_660061]( AUC inf)and l n(C max) of spi[INVESTIGATOR_74963] 0.[ADDRESS_660062](AUC inf)
and ln(C max) ofhydrochlorothiazide , respectivel y, as obtained from the literature (Xu et al, 
2008; Fierro Humberto, 2016 ).
Approximately  40participants will be enrolled in the study  ( 20ineach treatment sequence) 
to ensure at least [ADDRESS_660063] 
to the primary  PK objective may be replaced at the discretion of the investigator upon 
consultation with the sponsor.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 5310. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: 
Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant docume nts 
(eg,advertisements) must be reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093]
,and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before imp lementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary  to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for 
clinical device research, and all other applicable local regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evalua tion of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 54In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against any immediate hazard, and 
of an y serious breaches of this protocol or of 
the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during th e course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of the study , 
including the risks and benefits, to the participant or their legall y authorized representative
and answer all questions regarding the stud y.The participant or their legally  authorized 
representative should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative (if allowed by  [CONTACT_427]) will be required to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, privacy  and data protection requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each participant or their legall y authorized representative is 
fully  informed about the nature and objectives of the study , the sharing of data related to the 
study ,
and possible risks associated with participation, including the risks associated with the 
processing of the participant’s personal data. 
The participant or their legall y authorized rep resentative must be informed that their personal 
study -related data will be used by  [CONTACT_10999]. 
The level of disclosure must also be explained to the participant or their legally  authorized 
representative .
The participant or their legall y authorized representative must be informed that their medical 
records may  be examined by  [CONTACT_17080] y Assurance auditors or other authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  [CONTACT_78273].
The investigator further must ensure that each study  participant or their legally  authorized 
representative is fully  informed about their right to access and correct their personal data and 
to withdraw consent for th e processing of their personal data.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 55The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which the written consent was 
obtained. The authorized person 
obtaining the informed consent must also sign the IC D.
Participants or their legally  authorized representative must be reconsented to the most current 
version of the IRB/EC -approved ICD(s) during their participation in the study as required per 
local regulations .
A cop y of the IC D(s) must be provided to the participant or the irlegall y authorized 
representative (if allowed by  [CONTACT_427]) .
Participants who are rescreened are required to sign a new ICD.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and 
will be password protected to ensure that onl y authorized study  staff have access. The study  
site will implement appropriate technical and organizational measures to ensure that the 
personal data can be recovered in the event of disaster. In the event of a potential personal 
data breach, the stud y site will be responsible for determining whether a personal data breach 
has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participa ntswith regard to the processing of personal 
data, participants will be assigned a single, 
participant -specific numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to their actual identity and medical record ID. In case of data 
transfer, the sponsor will protect the confidentiality of participant s’ personal data consistent 
with the c linical study agreement and applicable privacy  laws.
Information technology  systems used to collect, process, and store study -related data are 
secured b y technical and organizational securit y measures designed to protect such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or sy stems.
10.1.5. Committees Structure
Not applicable.
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a n E
-DMC.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 5610.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials
.gov (Clini calTrials.gov), the EudraCT /CTI S, and/or 
www.pfizer .com, and other public registries and websites in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial r esults on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. Thes e results are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].
EudraCT /CTI S
[COMPANY_007] posts clinical trial r esults on EudraCT /CTI Sfor [COMPANY_007] -sponsored interventional studies 
in accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts CSR sy nopses and plain- language study  results summaries on www.pfizer .com 
for [COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results 
areposted to www.clinicaltrials
.gov.CSR sy nopses will have personally  identifiable 
information anon ymized.
Documents within marketing applications
[COMPANY_007] complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary  documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally  identifiable information anony mized.
Data sharing
[COMPANY_007] provides researchers secure access to participant -level data or full CSRs for the 
purposes of “bona -fide scientific research” that contribute sto the scientific understanding of 
the disease, target, or compound class. [COMPANY_007] will make data from thes e trials available 
18months after study  completion. Participant -level data will be anon ymized in accordance 
with applicable privacy  laws and regulations. CSRs will have personall y identifiable 
information anon ymized.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 57Data requests are considered from qual ified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7.
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic form and are password -protected to prevent access by  [CONTACT_20011].
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source records and documents.
This verification may  also occur after study  completion. I t is important that the 
investigator(s) and their relevant personnel are available during the monitoring visits and 
possible audits or insp ections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study -critical data items and 
processes (eg, risk- based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on
-site monitoring) , are provided in the data management pla nmaintained 
and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this stud y must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the spo nsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 58with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the 
sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Befo re response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes a source document and its origin can be found in the Source 
Document Locator , which is maintained by  [CONTACT_103] .
Description of the use of the computerized sy stem is documented in the Data Management 
Plan, which is maintained by  [CONTACT_456] .
The investigator must maintain accurate docume ntation (source record) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; 
that the safet y and rights of participants are being protected; and that the study is being 
conducted in accordance with the currentl y approved protocol and an y other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. U se of Medical Records
There may  be instances when copi[INVESTIGATOR_296040] , where ethically  and scientifically  justified and permitted by  [CONTACT_427], 
to ensure participant safety .
Due to the potential for a participant to be re -identified from their medical records, the 
following actions must be taken when medical records are sent to the sponsor or sponsor 
designee:
The investigator or site staff must redact personal information from the medical 
record. The personal information includes, but is not limited to, the following: 
participant names or initials , participant dates (eg, birth date, date of hospi[INVESTIGATOR_15517]/discharge, date of death), participant identification numbers (eg, Social 
Security  number, he alth insurance number, medical record number, 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 59hospi[INVESTIGATOR_307]/institution identifier), p articipant location information (eg, street address, 
city, country , postal code, I P address), participant contact [CONTACT_3031] (eg, 
telephone/fax number, email address) .
Each m edical record must be transmitted to the sponsor or sponsor designee using 
systems with technical and organizational security  measures to ensure the protection 
of personal data (eg, Florence is the preferred s ystem if available).
There may be unplanned sit uations where the sponsor may  request medical records (eg, 
sharing medical records so that the sponsor can provide study -related advice to the 
investigator). The medical records should be submitted according to the procedure described 
above.
10.1.10. Study and Site Start and Closure
The study  start date is the date of the first participant’ s first visit.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor ,including (but not limited to) 
regulatory  authorit y decision, change in opi[INVESTIGATOR_2511] I RB/EC, or change in benefit -risk 
assessment .Study  sites will be closed upon study completion. A study  site is considered 
closed when all required documents and study  supplies have been collected and a study -site 
closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants
.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authoriti es, the sponsor ’s procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the E Cs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate participant therapy  and/or follow -
up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 6010.1.11. Publication Policy
For multicenter trials, the primary  publication will be a joint publication developed b y the 
investigator and [COMPANY_007] reporting the primary  endpoint(s) of the study  covering all study  sites. 
The investigator agrees to refer to the prima ry publication in any  subsequent publications. 
[COMPANY_007] will not provide any financial compensation for the investigator’s participation in the 
preparation of the primary congress abstract, poster, prese ntation, or primary  manuscript for 
the study .
Investiga tors are free to publish individual center results that they  deem to be clinically  
meaningful after publication of the overall results of the study  or [ADDRESS_660064] to the other 
requirements described in this section.
The investigator will provide [COMPANY_007] an opportunity  to review any  proposed publication or 
any other t ype of disclosure of the study  
results (collectively , “publication”) before it is 
submitted or otherw ise disclosed and will submit all publications to [COMPANY_007] 30days before 
submission. If any patent action is required to protect intellectual propert y rights, the 
investigator agrees to delay  the disclosure for a period not to exceed an additional [ADDRESS_660065], remove an y previousl y undisclos ed 
confidential information before disclosure, except for an y stud y
-intervention or [COMPANY_007] -related 
information necessary  for the appropriate scientific presentation or understanding of the 
study  results. For joint publications, should there be disagreement regarding interpretation 
and/or presentation of specific anal ysis results, resolution of, and responsibility  for, such 
disagreements will be the collective responsibility  of all authors of the publication .
For all publications relating to the stud y, the i nvestigator and [COMPANY_007] will comply  with 
recognized ethical standards concerning publications and authorship, including those 
established by  [CONTACT_4717]. The i nvesti gator will 
disclose an y relationship with [COMPANY_007] and any  relevant potential conflicts of interest, including 
any financial or personal relationship with [COMPANY_007] ,in any  publications. All authors will have 
access to the relevant statistical tables, figures , and reports (in their original format) required 
to develop the publication .
10.1.12. Sponsor’s Medically Qualified 
Individual
The contact [CONTACT_1133] ’s MQI for the study  is documented in the study  
contact [CONTACT_185623] y documentation/study  portal or other electronic 
system .
To facilitate access to their investigator and the sponsor ’s MQI for study -related medical 
questions or problems from non -study  healthcare professionals, participants are provided 
with an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol 
and study  intervention identifiers, (b) participant’s study  identification number, (c) site 
emergency  phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] C all C enter 
number.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 61The ECC is intended to augment, not replace, the estab lished communication pathway s 
between the participant and their investigator and site staff, and between the investigator and 
sponsor 
study  team. The ECC is only to be used by  [CONTACT_185624] y, as a means of reaching the investigator or site staff related to the care of a 
participant. The [COMPANY_007] Call Center number is to be used when the investigator and site staff 
are unavailable . The [COMPANY_007] Call Center number is not for use by  [CONTACT_185625] y; if a 
partic ipant calls that number directly , they will be directed back to the investigator site.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 6210.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the 
SoA section of 
this protocol. Additional laboratory  results may be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] ,or as derived 
from calculated values; for example: c alculation of estim ated kidney  function . These 
additional tests would not require additional collection of blood. Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
Table 5. Protocol -Required Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)Urea
Creatinine
Cystatin Ca
eGFR
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosp hatase
Uric acid
Albumin
Total proteinLocal dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Laboratory:
Microscopy and 
culturebAt screen ing:
FSHc
Urine drug screeningd
Hepatitis B surface 
antigen
HBcAb
Hepatitis C antibody
HIV
Pregnancy test ( β-hCG)e
a.Cystatin C (Scys): Screening or Baseline Scys is recommended to help differentiate post -baseline DIKI 
from DICI. Post -baseline, Scys is measured if and only if serum creatinine increase post- baseline is observed 
(see Section 7.1.1 ).
b.Only if UTI is suspected and urine dipstick is positive for nitrites or leukocyte esterase or both .
c.For confirmation of postmenopausal status only in females <60 years old and not using hormonal or 
HRT only .
d.The minimum requirement for drug screening includes coca ine, THC, marijuana,opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site -and study -specific).
e.Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_216483]/EC. See SoA for collection times.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the CRF.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 6310.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
Note: An A E can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scie ntific judgment of the investigator. Any 
abnormal test results that meet an y of the conditions below must be recorded as 
an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including a n 
increase in either frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug- drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-
harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 64Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_227926] A Es. 
If a complication prolongs hospi[INVESTIGATOR_23919], the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.
d.Results in persistent or significant disability/incapacity

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 65The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) ,thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an i nfectious agent, 
pathogenic or non -pathogenic 
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed to a [COMPANY_007] product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases b y 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g.Other situations:
Medical or scientific ju dgment should be exercised by [CONTACT_78278], such as significant 
medical events that may jeopardize the participant or may  require medical or 
surgical intervention to prevent one of th e other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasi as or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of A Esand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs using the CT SAE Report Form to [COMPANY_007] Safety throughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonserious A Es; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must 
be completed in a consistent manner. A Es should be recorded using concise medical 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 66terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll A Es/SAEs associated 
with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRFAll instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not
there is an associated 
SAE)**
Environmental or 
occupational exposure 
to the product under 
study  to a 
nonparticipant (not 
involving EDP or EDB)None. Exposure to a study 
non-participant is not 
collected on the CRFThe exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported***
*EDP (with or without an associated SAE): is reported to [COMPANY_007] Safety using the CT SAE Report 
Form and EDP Supplementa l Form . 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form ,which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form
When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_469466]-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 67records before submission to [COMPANY_007] Safety .Refer to Section 10.1.[ADDRESS_660066] be taken when medical records are sent to the sponsor or sponsor designee.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clin ical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories:
Mild: A type of AE that is usually  transient and may  require only  minimal 
treatment or therapeutic intervention. The event does not generally  interfere with 
usual ADL .
Moderate: A t ype of AE that is usually  alleviated with additional specific 
therapeutic intervention. The event interferes with usual ADL , causing 
discomfort , but poses no significant or permanent risk of harm to the research 
participant.
Severe: A t ype of AE that interrupts usual ADL , or significant ly affects clinical 
status, or may  require intensive therapeutic intervention.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship convey s that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the tempor al relationship of the event to study intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for 
marketed products, in their assessment.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 68For each AE or SAE, the investigator mustdocument in the medical notes that 
they have reviewed the AE or SAE and ha veprovided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor .However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor .
The investigator may  change their opi[INVESTIGATOR_19954] -up
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for 
reporting purposes, as defined by  [CONTACT_456] . In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow -Up of A Es and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically  indicated or as 
requested b y the sponsor ,to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers .
If a participant dies during p articipation in the study  or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings, including histopathology .
New or updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 
24
hours of receipt of the information.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 6910.3.4. Reporting of SAE s
SAE Reporting to [COMPANY_007] Safety via an Electronic DCT
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic DCT (eg, eSAE or PSSA) .
If the electronic s ystem is unavailable, then the site will use the paper SAE report 
form (see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) or 
paper form (as applicable) as soon 
as the data become available.
After the stud y is completed at a given site, the electronic DCT will be taken 
off-line to prevent the entry  of new data or changes to existing data.
If a site receives a rep ort of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic DCT has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_199097].
SAE Reporting to [COMPANY_007] Safety via the CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is one of the method sto 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , an alternative method should 
be used, eg, secured (Transport L ayer Security ) or password- protected email. I f 
none of these methods can be used, notification by [CONTACT_9337] a 
copy  of the CT SAE 
Report Form sent b y overnight mail or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 7010.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 
[ADDRESS_660067] dose of stud y intervention, which 
corresponds to th e time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse as their preferred and usual lifesty le 
(abstinent on a longterm and persistent basis) and agree to remain abstinent. 
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom, and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception, as a condom 
may break o r leak when having sexual intercourse with a WOCBP who is not 
currentl y pregnant.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1) and specify  
the reproductive requirements for including female participants. Refer to Section 10.4.[ADDRESS_660068] 1 of the following conditions applies:
Is not a WOCBP (see definition in Section 10.4.3
).
OR
Is a WOCBP and agrees to use a highl y effective contraceptive method (failure rate of 
<1% per year) during the intervention period and for at least [ADDRESS_660069] dose 
of study  intervention, which corresponds to the time needed to eliminate any  
reproductive safet y risk of the study intervention(s). If a highl y effective, 
user-dependent method is chosen, she agrees to concurrentl y use an effective barrier 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 71method of contraception. The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, a menorrhea 
or oligomenorrhea ) and a menstrual cy cle cannot be 
confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1. Premenopausal female with 1 of the f ollowing:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to a medical cause other than the above
(eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be applied 
to determining stud y entry.
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview. The method of d ocumentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT.
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the highl y effective nonestrogen hormonal contraception methods 
if she wishes to continue herHRT during the study . Otherwise, she must 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 72discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study :
Highl y Effective Methods That H ave Low User Dependency
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.
5.Vasectomized partner.
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatogenesis cy cle is approximately  90days.
Highl y Effective Methods T hat A re User Dependent 
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral + barrier *
Intravaginal + barrier *
Transdermal + barrier *
7.Progestogen -only hormone contraception associated with inhibition of ovulation:
Oral + barrier *
Injectable + barrier *

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 73Sexual Abstinence
8.Sexual abstinence is con sidered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be evaluated 
in relation to the duration of the study  and the preferred and usual lifest yle of the 
participant .
* Acceptable barrier methods to be used concomitantly  with options 6 or 7 for the stud y 
include an y of the following:
Male or female condom ,with or without spermicide;
Cervical cap, diap hragm or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm ,or sponge 
with spermicide (double -barrier methods).
10.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  benarrow (eg, 1or more candidate gen es) or
broad (eg,the entire genome ),as appropriate to the scientific question under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to Spi[INVESTIGATOR_8407]/Hy drochlorothiazide or study  interventions 
of this class to understand treatments for the disease(s) under study  or the disease(s) 
themselves.
The results of genetic analy ses may  be reported in the CSR or in a separate study  
summary , or may  be used for internal decision maki ng without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality .
The samples will be retained as indicated:
Retained samples will be stored indefinitely  or for another period as per local 
requirements.
Participant s may  withdraw their consent for the storage and/or use of their Retained 
Research Samples at an y time by  [CONTACT_7328] a request to the investigator; in this case, an y 

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 74remaining material will be destro yed. Dat a alread y generated from the samples will be 
retained to protect the integrity  of existing anal yses.
Samples for genetic research will be labeled with a code. The key  between the code 
and the participant ’s personally  identify ing information (eg , name, addr ess) will be 
held 
securely  at the study site.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 7510.6. Appendix 6: Liver Safety: Suggested Actions and Follow
-Up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury , commonl y referred to as DILI. 
Participant s who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
LFTs are not required as a routine safety  monitoring procedure in this study . However, 
should an investigator deem it necessary  to assess LFTs because a participant presents with 
clinical signs/s ymptoms, such LFT results should be managed and followed as described 
below.
In the majority  of DILI cases, elevations in AST and/or ALT precede T bili elevations 
(>2×ULN) by  [CONTACT_90051] s or weeks. The increase in T bili typi[INVESTIGATOR_214318]/AL T is/are still elevated above 3 × ULN (ie, AST/AL T and T bili values will be 
elevated within the same lab oratory sample). In rare instances, by  [CONTACT_29623] T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be cons idered important medical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. 
Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and T bili baseline va lues within the normal range who 
subsequently  present with AST OR AL T values ≥3 × ULN AND a T bili value ≥2 × ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available.
For participant s with baseline AST 
OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values ≥
2times the baseline values AND ≥3 ×ULN; or ≥8 × ULN (whichever is 
smaller).

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 76Preexisting values of T bili above the normal range: T bili level increased from 
baseline value b y an amount of ≥ 1 × ULN orif the value reaches ≥
3 ×ULN 
(whichever is smaller).
Rises in AST/AL T and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_660070] and AL T and T bilifor suspected Hy ’s law 
cases , 
additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, eosinophils (%) , 
and alkaline phosphatase. Consideration should also be
given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology . A detailed history , including relevant information, 
such as review of ethanol, acetaminophen /paracetamol (either b y itself or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C , D, and E infection, total bile acids, liver imaging (eg, biliary  tract) ,and 
collection of serum sample
sfor acetaminophen /paracetamol drug and/or protein adduct 
levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/AL T and 
T bili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of a vailability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have exclud ed an alternative etiology .

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 7710.7. Appendix 7: Kidney Safety: Monitoring Guidelines
10.7.1.
Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney  safety  monitoring requires assessment of baseline and postbaseline Screat 
measurement to estimate kidney function [Screat -based eGFR]). Obtaining Screening or 
Baseline Scy s and postbaseline reflex Scy s (if confirmed Screat increase ≥0.3 mg/dL) makes 
it feasible to distinguish AKI from DI CI. If Screat increase is confirmed after baseline, then 
reflex measurement of Scy s is indicated:
ADULTS: Currentl y, 2021 CKD -EPI [INVESTIGATOR_336252] (Screat -only based and combined 
Screat plus Scy s-based) are valid for use in adults only . At baseline Screat and Scy s values 
are needed to calcula te 2021 CKD -EPI [INVESTIGATOR_510458] -only based equation (see Table in 
Section [IP_ADDRESS]) and b y combined Screat plus Scys -based equation. When post -baseline 
Screat incre ase ≥0.3 mg/dL  is confirmed, then reflex Scy s measurement is needed to enable 
post-baseline comparison of eGFR changes (Screat
-only based eGFR and combined Screat 
plus Scy s eGFR).
Regardless of whether kidney  function monitoring tests are required as a rou tine safet y 
monitoring procedure in the study , if the investigator or sponsor deems it necessary  to further 
assess kidney  safety  and quantify  kidney  function, then these test results should be managed 
and followed per standard of care.
10.7.2. Age-Specific Kidney Fu nction Calculation Recommendations
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD- EPI [INVESTIGATOR_227929] (mL/min/1.73m²) (Inker et al, 2021 )
2021 
CKD -EPI
[INVESTIGATOR_227931]
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 NA eGFR = 143 × (Scr eat/0.7)-0.241× (0.9938)Age
Female if > 0.7 NA eGFR = 143 × (Scr eat/0.7)-1.200× (0.9938)Age
Male if ≤ 0.9 NA eGFR = 142 × (Scr eat/0.9)-0.302× (0.9938)Age
Male if > 0.9 NA eGFR = 142 × (Scr eat/0.9)-1.200× (0.9938)Age
2021 
CKD -EPI 
[INVESTIGATOR_227932]-Scys 
CombinedScreat
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤ 0.7 if ≤ 0.8 eGFR = 130 × (Scr eat/0.7)-0.219× (Scys/0.8)-0.323× (0.9961)Age
Female if ≤ 0.7 if > 0.8 eGFR = 130 × (Scr eat/0.7)-0.219× (Scys/0.8)-0.778× (0.9961)Age
Female if > 0.7 if ≤ 0.8 eGFR = 130 × (Scr eat/0.7)-0.544× (Scys/0.8)-0.323× (0.9961)Age
Female if > 0.7 if > 0.8 eGFR = 130 × (Scr eat/0.7)-0.544× (Scys/0.8)-0.778× (0.9961)Age
Male if ≤ 0.9 if ≤ 0.8 eGFR = 135 × (Scr eat/0.9)-0.144× (Scys/0.8)-0.323× (0.9961)Age
Male if ≤ 0.9 if > 0.8 eGFR = 135 × (Scr eat/0.9)-0.144× (Scys/0.8)-0.778× (0.9961)Age
Male if > 0.9 if ≤ 0.8 eGFR = 135 × (Scr eat/0.9)-0.544× (Scys/0.8)-0.323× (0.9961)Age
Male if > 0.9 if > 0.8 eGFR = 135 × (Scr eat/0.9)-0.544× (Scys/0.8)-0.778× (0.9961)Age

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 7810.7.3. Kidney Function Calculation Tools
The sponsor has provided the following resources to investigational sites when required to 
calculate age -specific kidney  function at Screening, Baseline, and post
-Baseline visits. Site 
calculations of kidney  function can be performed manually , using the age appropriate 
formulae (see Section 10.7.2 ) and can use recommended online kidney  function calculators 
to reduce the likelihood of a calculation error. 
The [LOCATION_002] National Kidney  Foundation Online Calculators. 
Adults (18 y ears and above) - 2021 CKD -EPI [INVESTIGATOR_227933] (eGFR): 
https://www.kidney .org/professionals/KDOQI /gfr_calculator
Investigational sites are responsible to ensure that the accurate age -specific equation is 
selected and that the correct units are used for serum creatinine (mg/dL only ), serum 
cystatin C (mg/L onl y), total body weight (kg only), and age (years). Investigators are 
expected to (i) review and confirm correctn ess of the kidney  function calculation results and 
(ii) evaluate the calculated value within the context of historical information available to 
them in the participant’s medical record. Investigators are responsible for the clinical 
oversight of the partic ipant eligibility  process, kidney  function calculation, and dose selection 
and adjustments per study  protocol. Investigators are encouraged to direct questions or 
uncertainties regarding kidney  function and dosing to the [COMPANY_007] Clinical Team and Medical 
Monitor, if needed.
10.7.4. Adverse Event Grading for Kidney Safety Lab oratory Abnormalities
AEgrading for decline in kidney  function (ie, eGFR) will be according to Kidney  Disease: 
Improving Global Outcomes (KDIGO) criteria for adult participants.
KDIGO criteria 
grade (G)Study 
PopulationG1 G2 G3 G4 G5
Decreased Kidney 
Function due to 
either Acute or 
Chronic Kidney 
InjuryAdult 
participants
eGFR 
(mL/min/1.73m²)≥90 ≥60 to 89 30 to 59 15 to 29 <15
KDIGO albuminuria (A) criteria A1 A2 A3
Albumin -to-creatinine ratio (ACR) <30 mg/g
OR
<3 mg/mmol 30 to 300 mg/g
OR
3 to 30 mg/mmol>300 mg/g
OR
>30 mg/mmol

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 7910.8. Appendix 8: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus brad ycardia (rate <40 bpm) lasting minutes .
New PR interval prolongation >280 ms .
New prolongation of QTcF to >480 ms (absolute).
New prolongation of QTcF b y >60 ms from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -onset t ype I second-degree (Wenckebach) AV block of > 30-second duration .
Frequent PVCs, t
riplets, or short intervals (<30 seconds) of consecutive 
ventricular complexes.
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms .
Absolute value of QTcF > 450 ms AND QTcF change from baseline >60 ms.
New ST- T changes suggestive of my ocardial ischemia .
New -onset LBBB (QRS complex >120 ms) .
New -o
nset right bundle b ranch block (QRS complex >120 ms) .
Symptomatic bradycardia .
Asystole
In awake, s ymptom -free participant s in sinus rhy thm, with documented 
asystolic pauses ≥3seconds or an y escape rate <40 bpm, or with an escape 
rhythm that is below the AV node ;
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_660071] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 80Sustained s upraventricular tachycardia (rate >120 bpm) ( “sustained ”= short 
duration with relevant s ymptoms or lasting >1 minute) .
Ventricular r hythms >30 second duration, including idioventricular rhy thm ( HR
<40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm
),and 
monomorphic/poly morphic ventricular tachycardia (HR >100 bpm [such as
torsades de pointes]).
Type II second -degree (Mobitz II) AV block.
Complete (third- degree) h
eart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30-seconds duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrhy thmia classified as an adverse 
experience .
The major events of potential clinical concern listed above are recommended as “alerts ”or notifications 
from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be considered as all-
inclusive of what is to reported as AEs/SAEs.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 8110.9. Appendix 9:Prohib ited Concomitant Medications That May Result in DDI
The prohibited concomitant medications listed below should not be taken with 
Spi[INVESTIGATOR_8407]/Hy drochlorothiazide for the period of time at least equal to ,the required 
washout period listed in the table, and throughout the conduct of the stud y.
The [COMPANY_007] study team is to be notified of any  prohibited medications taken during the study . 
After consulting with the spo nsor, the investigator will make a judgment on the ongoing 
participation of an y participant with prohibited medication use during the study.
This list of drugs prohibited for potential DDI concerns with the IMP may  be revised during 
the course of the study with written notification from the 
sponsor to include or exclude 
specific drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, 
availability  of new information in literature on the DDI potential of other drugs) if the overall
benefit/risk assessment is not impacted or if the changes do not significantly impact the 
safet y of participants or the scientific value of the trial .
This is not an all -inclusive list. Site staff should consult with the sponsor or designee with 
any quest ions regarding potential DDI.
Drug Category Drugs Required Washout Period R equirement
ACE inhibitors Benazepril, Captopril, 
Enalapril, Fosinopril, 
Lisinopril, Moexipril, 
Perindopril, Quinapril, 
Ramipril, Trandolapril5 days
or
5 half -lives
whichever is longer
Angiotensin II Receptor 
antagonistsLosartan, telmisartan, 
irbesartan, Olmesartan, 
valsartan5 days
or
5 half -lives
whichever is longer
Aldosterone blockers Eplerenone, Finerenone 3 days
or
5 half -lives
whichever is longer
Potassium supplements Potassium iodide, Potassium 
chloride5 days
or
5 half -lives
whichever is longer
Anticoagulants Heparin, low  molecular 
weight heparin8 hours
or
5 half -lives
whichever is longer
Alcohol Ethyl alcohol 1 day
or
5 half -lives
whichever is longer
Antidiabetic drugs Insulin, sulphonylureas, 
Biguanides, meglitinides, 
thiazolidinediones, Alpha 
glucosidase inhibitors2 weeks
or
5 half -lives
whichever is longer

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 82Drug Category Drugs Required Washout Period R equirement
Corticosteriods, ACTH Hydrocortisone, 
Dexamethasone, 
methylprednisone and 
prednisone1 day
or
5 half-lives
whichever is longer
Pressor amines Norepi[INVESTIGATOR_238], 
phenylephrine, ephidrine1.5 days
or
5 half -lives
whichever is longer
Skeletal muscle relaxants, 
nondepolarizingTubocuraine 10 hours
or
5 half -lives
whichever is longer
Antimaniac/Antidepressant lithium 5 days
or
5 half -lives
whichever is longer
NSAIDs Indom ethacin, Dyclofenac, 
Aceclofenac, ibuprofen, 
naproxen, aspi[INVESTIGATOR_248], 
acetylsalicylic acid1 day
or
5 half -lives
whichever is longer
Cardiac glycoside Digoxin 2 weeks
or
5half-lives
whichever is longer
Bile acid sequestrant Cholestyramine 5 hours
or
5 half -lives
whichever is longer
Androgen biosynthesis 
inhibitorAbiraterone 3.5 days
or
5 half -lives
whichever is longer
Investigators should consul t the USPI [INVESTIGATOR_510459]/Hy drochlorothiazide for
information regarding medication that is prohibited for concomitant use.
Investigators should consult the product label for any  other medication used during the study  
for information regarding medication that is prohibited for concomitant use.

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 8310.10. Appendix 10: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
A1 to A3 albuminuria (KDIGO albuminuria severit y standardization)
Abs absolute
ACE angiotensin -converting enzy me
ACR albumin -to-creatinine ratio
ACTH adrenocorticotropic hormone
ADL activit y/activities of dail y living
AE adverse event
AESI adverse event of special interest
AKI acute kidney  injury
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the curve
AUC inf area under the plasma concentration -time profile from time [ADDRESS_660072] quantifiable concentration (C last)
AV atrioventricular
AxMP auxiliary  medicinal product
BA bioavailability
BE bioequivalence
β-hCG -human chorionic gonadotropin
BMI body  mass index
BP blood pressure
bpm beats per minute
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_510460] 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_660073] clinical trial
CTIS Clinical Trial I nformation Sy stem

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 84Abbreviation Term
DCT data collection tool
DDI drug-drug interaction 
DICI drug-induced creatinine increase
DIKI drug-induced kidney  injury
DILI drug-induced liver injury
EC ethics committee
ECC emergency  contact [CONTACT_510469]
E-DMC External Data Monitoring Committee
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
eSAE electronic serious adverse event
EU European Union
EudraCT European Union Drug Regulating Authorities Clini cal Trials 
(European Clinical Trials Database )
f2 degree of similarity
FSH follicle -stimulating hormone
F/U follow -up
G1 to G5 Grade (KDIGO eGFR category  standardization)
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
HBcAb hepatitis B core antibod y
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCTZ Hydrochlorothiazide
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ID identification
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IPAL Investigational Product Accountability  Log
IPM investigational product manual
IRB Institutional Review Board
KDIGO Kidney  Disease Improving Global Outcomes

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 85Abbreviation Term
kel first-order elimination rate constant
LBBB left bundle branch block
LFT liver function test
MQI medically  qualified individual
NA not applicable
NDA New Drug Application
NIMP noninvestigational medicinal product
NSAID Non-Steroidal Anti -Inflammatory  Drug
PD pharmacod ynamic(s)
PGS [COMPANY_007] Global Supply
PR pulse rate
PK pharmacokinetic(s)
PSSA [COMPANY_007]'s Serious Adverse Event Submission Assistant
PT prothrombin time
PVC premature ventricular contraction/complex
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
qual qualitative
RBC red blood cell
RNA ribonucleic acid
RSD relative standard deviation
SAE serious adverse event
SAP Statistical Analy sis Plan
Screat serum creatinine 
Scys serum cy statin C
SoA schedule of activities
SOP standard operating procedure
SRSD Single Reference Safety  Document
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t½ terminal elimination half -life
T bili total bilirubin
THC tetrah ydrocannabinol
Tmax time for C max
ULN upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_185578] I nformation
UTI urinary  tract infection
WBC white blood cell
WOCBP woman/women of childbearing potential

PF-06832640
Protocol B9 531002
Final Protocol , 
28September 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Pharmacology Protocol Template ( 14April 2023)
Page 8611.REFERENCES
CDS. Spi[INVESTIGATOR_8407]/Thiazide Core Data Sheet (CDS). 14 April 2022(Version 12.0).
Fierro Humberto RR, Yáñez Sebastian, Acuña Paola, Rosales Katherine, Yevenes Paulina, 
Yzoard Marcia, Tapia Claudia, Rivas Violeta, Caba Alvaro, Copaja Miguel, Jorge 
Fuentealba. Bioequivalence Study  of Two Hy drochlorothiazide Formulations after Oral 
Administration in Healthy  Chilean Volunteers. Journal of Pharmacy  and Pharmacology  (El 
Monte). 2016;4(12):679-
85.
Inker LA, Enean ya ND, Coresh J, et al. New Creatinine -and Cy statin C -Based Equations to 
Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-49.
Spi[INVESTIGATOR_510461] d Hy drochlorothiazide Tablet, US Prescription I nformation (USPI ) 
[Internet]. Prasco Laboratories. 09 January  2023 [cited 18 Aug 2023]. Available from: 
https://daily med.nlm.nih.gov/dail ymed/fda/fdaDrugXsl.cfm?setid=9d350fa2-d568-4970-
a7a5 -d128ff5d0a2f&t ype=display .
Xu FG, Zhang ZJ, Dong HJ, et al. Bioequivalence assessment of two formulations of 
spi[INVESTIGATOR_510462] y male volunteers. Arzneimittelforschung. 2008;58(3):117 -
21.
